 Immunovant Sciences Gm bH Protocol RVT -1401- 2002, Version 3.0 
Confidential  1  
CLINICAL STUDY PROTOCOL 
Title:  A Phase 2a, Multicenter, Randomized, Double -Blind, Placebo -
Controlled Study with  an Open-Label Extension of RVT -1401 in 
Myasthenia Gravis Patients  
Sponsor  Immunovant Sciences GmbH, a Swiss Limited Liability Company, is 
the Sponsor of this study. Immunovant, Inc., an affiliate of 
Immunovant Sciences GmbH, has been engaged by Immunovant 
Sciences GmbH to manage the day -to-day operations of the study. All 
references to “Sponsor” contained herein shall refer to Immunovant, Inc., acting pursuant to a servic es agreement with Immunovant 
Sciences GmbH.  
Compound Name : RVT -1401 
Protocol Number RVT -1401-2002 
Indication  Myasthenia Gravis  
Development Phase  2a 
IND # 141885 
Version/  
Effective Date:  Amendment 2: Version 3.0 
10-APR -2019 
Amendment 1 : Version 2.0 
18-JAN-2019 
Original : Version 1.0  
04-DEC -2018  
Imm unov ant, Inc.  
Study Director  Telephone:Email:
Confidentiality Stateme nt 
The information contained in this document, particularly unpublished data, is the proper ty or under control of Sponsor , 
and is provided to you in confidence as an investigator, potential investigator or consultant, for review by you, your 
staff, and an app licable Institution al Review Board or Independent Ethics Committee. The information is only to be 
used by you in connection w ith authorized clinical studies of the investigational drug described in the protocol. You 
will not disclose any of the information to others without written authorization from Sponsor , except to the extent 
necessary to  obtain informed consent from those persons to whom the drug may be administered.  

 Immunovant Sciences Gmb H RVT-1401- 2002, Versio n 3.0 
 
Confidential  2 SPONSOR SIGNATURE PA GE: 
Study title: A Phase 2a , Multicenter, Randomized, Double-Blind, P lacebo -Controlled 
Study with an Open -Label Extension of RVT -1401 in  Myasthenia Gravis Patients    
Protocol Number: R VT-1401-2002 
 
This protocol has been approved by Sponsor’s representative . The  following signature 
documents this approval. 
Immunovan
t, Inc.   Date  
  

 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 4 INVESTIGATOR STATEMENT 
• I confirm agreement to conduct the study in compliance with the protocol. 
• I acknowledge that I am responsible f or overall study conduct. I agree to personally 
conduct or supervise the described study. 
• I agree to ensure that all associates, colle agues and employees assisting in the 
conduct of the study are informed about their oblig ations and comply with the study 
protocol . Mechanisms are in place to ensure that site staff receives the appropriate 
information  throughout the study. 
 
______________________________________ ______________________________ Principal Investigator Name (P rinted)   Signature 
 
______________________________________ ______________________________ 
Site       Date  
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 5  
1. TABLE OF CONTENTS  
PAGE  
1. TABLE OF CONTENTS  ........................................................................................... 5  
2. PROTOCOL SUMMARY FOR  STUDY RVT -1401 -2002  ........................................... 8  
3. INTRODUCTION  .................................................................................................... 11 
3.1. Background  ................................................................................................ 11 
3.1.1.  Myasthenia Gravis  ....................................................................... 11 
3.2. Rationale .................................................................................................... 12 
3.2.1.  Study  Rationale ........................................................................... 12 
3.2.2.  Dose rationale ............................................................................. 12 
3.2.3.  Clinical Experience  ...................................................................... 14 
3.2.3.1.  Safety  ......................................................................... 15 
3.2.3.2.  Pharmacokinetics  ....................................................... 15 
3.2.3.3.  Pharmacodynamic  ...................................................... 16 
3.3. Benefit: Risk Assessment  ........................................................................... 17 
3.3.1.  Risk Assessment  ......................................................................... 17 
4. OBJECTIVE(S) AND END POINT(S)  ...................................................................... 19 
5. STUDY DESIGN  .................................................................................................... 20 
5.1. Overall Design  ............................................................................................  20 
5.2. Study Schematics  ....................................................................................... 22 
5.3. Treatment Arms and Duration  ..................................................................... 22 
6. PARTICIPANT POPULATI ON ................................................................................ 23 
6.1. Ty
pe and Number of Participants  ................................................................ 23 
6.2. Inclusion Criteria  ......................................................................................... 23 
6.3. Exclusion Criteria  ........................................................................................ 24 
6.4. Eligibility for the OLE  .................................................................................. 26 
6.5. Other Eligibility Criteria Considerations  ....................................................... 26 
6.6. Screening/ Baseline Failures  ....................................................................... 26 
6.7. Lifestyle Restrictions  ................................................................................... 26 
6.7.1.  Contraception .............................................................................. 26 
6.8. Withdrawal Criteria  ..................................................................................... 27 
6.8.1.  Reasons for Withdrawal ............................................................... 27 
6.8.2.  Participant Withdrawal Procedures  .............................................. 28 
6.9. Stopping Criteria for Individual Participants  ................................................. 28 
6.9.1.  Liver Chemistry Stopping Criteria  ................................................ 28 
6.
9.2. Criteria for Permanent Discontinuation of Study Treatment 
in Association with Liver Test Abnormalities  ................................ 29 
6.9.3.  QTc Withdrawal Criteria  ............................................................... 29 
6.9.4.  Albumin Monitoring Criteria  .......................................................... 30 
6.10.  Toxicity Manag ement Criteria  ..................................................................... 31 
6.10.1.  Toxicity Management Criteria (AEs, Cardiovascular, and Site Reactions)  ............................................................................ 31 
6.10.2.  Other Management Criteria ......................................................... 32 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 6 6.11.  Participant and Study Compl etion ............................................................... 32 
7. STUDY TREATMENT  ............................................................................................  32 
7.1. Invest igational Product and Other Study Treatment  .................................... 32 
7.2. Treatment Assignment  ................................................................................ 34 
7.3. Blinding  ....................................................................................................... 34 
7.4. Packaging and  Labeling .............................................................................. 34 
7.5. Preparation/Handling/Storage/Accountability  .............................................. 35 
7.6. Compliance with Study Treatment  Administration  ....................................... 35 
7.7. Treatment of Study Treatment Overdose  .................................................... 36 
7.8. Treatment After the End of the Study  .......................................................... 36 
7.9. Concomitant Medications and Non -Drug Therapies  .................................... 37 
7.9.1.  Permitted Medications and Non- Drug Therapies  .......................... 37 
7.9.2.  Prohibited Medications and Non- Drug Therapies  ......................... 37 
8. STUDY ASSESSMENTS AN D PROCEDURES  ..................................................... 37 
8.1. Time and Events Table (12- week follow -up without OLE)  ........................... 38 
8.2. Time and Events Table (With OLE and 6- week follow -up) .......................... 41 
8.3. Screening and Critical Baseline Assessments  ............................................ 44 
8.4. Study Assessments and Procedures  .......................................................... 44 
8.4.1.  Physical Exams  ........................................................................... 44 
8.4.2.  Vital Signs  .................................................................................... 44 
8.4.3.  Electrocardiogram (ECG)  ............................................................. 44 
8.4.4.  Clinical Safety Laboratory Assessments  ...................................... 44 
8.4.5
. Pharmacokinetics  ........................................................................ 46 
8.4.6.  Anti-Drug Antibody (ADA) and Neutralizing Antibody 
(NAb)  ........................................................................................... 46 
8.4.7.  Pharmacodynamics  ..................................................................... 47 
8.4.8.  Exploratory Biomarkers  ................................................................ 47 
8.5. Myasthenia Gravis Assessments  ................................................................ 48 
8.5.1.  Myasthenia Gravis Activities of Daily Living (MG -ADL)  ................ 48 
8.5.2.  Quantitative Myasthenia Gravis Score (QMG)  ............................. 48 
8.5.3.  Myasth enia Gravis Composite Score (MGC)  ............................... 48 
8.5.4.  Myasthenia Gravis Quality of Life 15 revised Score (MG -
QOL 15r) ...................................................................................... 48 
8.5.5. Satisfaction Quest ionnaire ........................................................... 49 
9. DATA MANAGEMENT  ........................................................................................... 49 
10. STATISTICAL CONSIDERATIONS AND DATA ANAL YSES  ................................. 49 
10.1.  Sample Size Considerations  ....................................................................... 49 
10.2.  Data Analysis Considerations  ..................................................................... 49 
10.2.1.  Analysis Populations  ................................................................ ....
 49 
10.2.2.  Interim Analysis  ........................................................................... 50 
10.3.  Final Analysis  ............................................................................................. 50 
10.3.1.  Primary Endpoint for Efficacy  ....................................................... 51 
10.3.2.  Secondary Endpoints for Efficacy  ................................................ 51 
10.3.3.  Safety Analyses  ........................................................................... 52 
10.3.4.  Pharmacokinetic Analyses  ........................................................... 52 
10.3.5.  Pharmacodynamic Analyses  ........................................................ 52 
10.3.6.  Other Analyses  ............................................................................ 53 
10.3. 1
. OLE and Follow up Analyses  ....................................................... 53 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 7 11. ADVERSE EVENTS (AE) AND SERIOUS ADVERSE EVENTS (SAES)  ................ 53 
11.1.  Definition of Adverse Events  ....................................................................... 54 
11.2.  Definition and Reporting of Serious Adverse Events  ................................... 54 
11.3.  Time Period and Frequency for Collecting AE and SAE Inf ormation  ........... 55 
11.4.  Method of Detecting and Reporting AEs and SAEs  .................................... 56 
11.5.  Assessing Severity of AEs and SAEs  ......................................................... 56 
11.6.  Assessing Causality of AEs and SAEs  ........................................................ 57 
11.7.  Follow -up of AEs and SAEs  ........................................................................ 58 
11.8.  Regu latory Rep orting Requirements for SAEs  ............................................ 58 
11.9.  Overdose  .................................................................................................... 58 
12. PREGNANCY REPORTING  .................................................................................. 58 
13. RESPONSIBILITIES .............................................................................................. 59 
13.1.  Principal Investigator Responsibilities  ......................................................... 59 
13.1.1.  Good Clinical Practice (GCP)  ....................................................... 59 
13.1.2.  Institutional Review Board (IRB)/Independent Ethics 
Committee (IEC) Approval ........................................................... 59 
13.1.3.  Informed Consent  ........................................................................ 60 
13.1.4.  Confidentiality  .............................................................................. 60 
13.1.5.  Study Files and Retention of Records  .......................................... 61 
13.1.6.  Electroni c Case Report Forms (eCRF)  ........................................ 62 
13.1.7.  Drug Accountability  ...................................................................... 62 
13.1.8.  Inspections  .................................................................................. 63 
13.1.9.  Protocol C ompliance .................................................................... 63 
13.2.  Spons
or Responsibilities  ............................................................................. 63 
13.2.1.  Protocol Modifications  .................................................................. 63 
13.2.2.  Study Report and Publications  ..................................................... 63 
13.2.3.  Posting of Information on Publicly Available Clinical Trial Registers  ..................................................................................... 63 
13.3.  Joint Investigator/Sponsor Responsibilities  ................................................. 63 
13.3.1.  Access to Information for Monitoring ............................................ 63 
13.3.2.  Access to Information for Auditing or Inspections  ......................... 64 
13.3.3.  Study Discontinuation .................................................................. 64 
14. REFERENCES  ....................................................................................................... 65 
15. APPENDICES  ........................................................................................................ 67 
15.1.  Appendix 1: Abbreviations and Trademarks  ................................................ 67 
15.2.  Appendix 2: Liver Safety Required Actions and Follow up 
Assessments .............................................................................................. 70 
15.3.  Appendix 3: Protocol Amendment Summary of Changes  ............................ 72 
 
 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 8 2. PROTOCOL SUMMARY FOR STUDY  RVT-1401-2002   
Study Title  A Phase 2a, Multicenter, Randomized, Double -Blind, 
Placebo- Controlled Study with an Open -Label Extension of 
RVT-1401 in Myasthenia Gravis Patie nts 
Objectives  Primary  
To assess the safety and tolerability  of RVT -1401 in AChR 
antibody positive MG patients over a 6- week tr eatment 
period 
To examine t he effects of RVT -1401 on total IgG, IgG 
subclasses (1 -4) and anti -AChR- IgG levels  
Seconda ry 
To examine RVT- 1401 PK following repeat doses in 
patients with Myasthenia Gravi s (MG) 
To measure anti -RVT-1401 antibodies following repeat 
doses in patients with M G and assess any potential impact 
on PK or PD  
To examine the effects of RVT -1401 on the Quantitative 
Myasthenia Gravis (QMG) score  To examine the effects of RVT -1401 on the p roportion of 
patients with improvement on the QMG score by ≥ 3 points 
from baseli ne  
To examine the effects of RVT- 1401 on Myasthenia Gravis -
Activities of Daily Living score (MG -ADL)  
To examine the effects of RVT -1401 on the proportion of 
participants with a n improvement on the MG -ADL Score by 
≥2 points  
To examine the effects of RVT -1401 on the Myasthenia 
Gravis Composite (MGC) score  
To examine the effects of RVT -1401 on the proportion of 
participants with an improvement on the MGC Score by ≥3  
To examine t he effects of RVT -1401 on the Myasthenia 
Gravis Quality of Life (MG -QOL15r) score  
Open- Label Extension Objective:  
The objective of the OLE is to evaluate the effect of 
switching t o every  2-week dosing regimen of 340 mg R VT-
1401 on all study endpoints.  
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 9 Study Pha se Phase 2a 
Target Population  Myasthenia Gravis  
Number of Participan ts 
Planned Approximately 21 
Number of Study 
Centers Planned  Approximately 10-15 
Study De sign Phase 2a, random ized, dou ble-blind, placebo -controlled 
study , with an open -label extension (OLE) to investigate the 
safety, tolerability, PK, PD, and efficacy of two dosing 
regimens of RVT-1401  
Duration of Treatment  6 weeks  or 12 week s (3 additional  doses for the OLE)   
Criteria for Evaluation  
(Endpoints)  Primary  
Assessment o f safet y and tolerabi lity by analysis of adverse 
events ( AEs) data and changes from baseline in vital signs, 
clinical laboratory values, and electrocardiograms  
Change from baselin e in levels of total IgG and IgG 
subclasses (1 -4)  
Change from baseline in le vels o f anti-AChR- IgG 
Secondary 
PK Par ameters of AUC (0 -168 h) and maximum 
concentration (Cmax) after first and last dose  
Concentration of RVT- 1401 pre -dose (Ctrough)  
Immunogenicity determined by change from pre- dose in 
anti-RVT-1401 antibodies, character izatio n of any anti -
RVT-1401 to confirm neutralization potential  
Change from baseline in the QMG Score  
Proportion of participants with an improvement on the QMG 
score by ≥ 3 poi nts from baseline  
Change from baseline in the MG -ADL score  
Proportion of pa rticip ants with an i mpro vement on  the MG-
ADL Score by ≥2 points  
Change from baseline in the MGC score  
Proportion of participants with an improvement on the MGC 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 10 Score by ≥3 poi nts  
Change from baseline in the MG -QOL15r score  
 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 11 3. IN TRODUCTION 
3.1. Background 
RVT-1401 is a fully hum an anti-neonatal F c receptor (FcRn) monoclonal antibody.  
FcRn is critical to the reg ulation of Immunoglobulin G ( IgG) [Roopeni an, 2007 ]. In 
addition t o its central role in mediating the transport of IgG within and across cells o f 
diverse or igin, it also serves to rescue IgG from degradation, thereby prolo nging i ts 
circulating half -life [Roopenian, 2007].  Targeting the FcRn path way has been shown to 
dramatical ly reduce circulating IgG , thus supporting its use in the tre atment of auto- Ab 
mediated autoimmune diseases.   
3.1.1.  Myasthenia Gravis  
Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disease t hat causes 
weakness and fatigue. T he muscles that control eye and eyelid movement ar e particularly 
susce ptible to we akness , but other muscles for chewing, talking, and swallowing are 
freque ntly involved. Patients with ocular MG often progress to more sever e, generalized 
disease wit h involvement of bulbar, axial, limb, and/or respiratory m uscles .   
MG is part  of a spectr um of autoimmune diseases in which pathogenic IgG (pIgG) is 
thought to di rectly cause and/or exacerbate the condition.  MG results from bind ing of 
autoantibodies to proteins that lead to impaired tr ansmission at the neuromus cular 
junction. Most  com monly, in approximately 80% of MG patients,  anti-acetylcholine 
receptor (AChR) IgG is detected, and in a smaller subset (approximately 40 -50% of 
patient s who are seronegative for ant i-AChR IgG), anti- muscle -specific kinase receptor  
(MuSK) IgG is detected [ Gilhus , 2015]. Recently, autoantibodies against low-densit y 
lipoprotein related receptor protein 4 (Lrp4) have been described in se ronegative MG 
patien ts with varying frequencies rang ing from 2 to 50% [ Higu chi, 2011; Zisimopoulou,  
2014; Zh ang, 2012; Pevzne , 2012] . The clinical characteristics of Lrp4 -MG have yet to  
be fully characterized [ Evoli, 2015]. 
The chronic nature of  MG requires patients to cope with fluctuating symptoms and often 
maintain treatment with acetylcholinesterase inhibitors, corticosteroids, 
immu nosuppressants, plasma pheresis , and/or intravenous immunoglobulin [ Sanders , 
2016; Nowak , 2018]. Despite chronic treatment, up to 20% of MG patients can progress 
into myasthenic crisis [ Utsugisawa , 2014]. M G has wi despread and significant negative 
effects on quali ty of life including dai ly activities such as eating, walking, and speaking 
[Nowak , 2018]. Overall, the persistent muscle  weakness associated with MG ofte n 
negatively interferes with patients’ ability to engage in daily activities, including demands of work, family,  social functions, and physical activities [ Paul, 2001]. 
Cur
rent treatment guidelines recommend pyridostigmine as first lin e therapy with or 
without conc omitant corticosteroids for patients who are anti- AChR -IgG- positive  
[Sanders , 2016]. If corticosteroids are contraindicated, nonsteroidal immunosuppressive 
(IS) agent s are used , includ ing azathioprine ( AZA) , cyclosporine, mycophenol ate mofetil, 
methotrexat e, and tacrolimus. Despite exist ing treatment regi mens, cu rrent methods 
provide variable efficacy. Failure rates for current  treatm ents range from 15–53% 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 12 depending upon the presentation and diagnosis, and up to 20% of patients treat ed with IS 
agents experience severe side effects [ Sanders , 2010]. Thus, there is a need for more 
efficacious and safer therapies.  
 
3.2. Rationale 
3.2.1.  Stud y Rationale  
RVT -1401 functions by inhibiting the binding of IgG to FcRn . This results in the rapid 
catabolism of IgG via lysosomal degra datio n. In MG, RVT -1401 treatment  is expected to 
lead to a significant reduction in the levels of pIgG  such as anti -AChR -IgG, anti -MuSK-
IgG, and anti- Lrp4 -IgG that have been iden tified to drive dise ase path ology. While this 
initial Ph2a study will focus o n anti -AChR IgG posit ive pati ents to  reduce heterogeneity , 
future studies may also assess the effic acy of anti -FcRn blockade in seronegative 
patients.  
The purpose of the cur rent study is to confirm s afety/to lerability and key 
pharm acodynamic (PD) effec ts that are considered to  drive cl inical  bene fit (reduction of 
total IgG and anti -AChR -IgG) in MG patients. A positive correlation between total and 
pIgG reduction and clinical impr ovement in MG patients  has been previously observed 
with another anti -FcRn treat ment (ARGX -113). A 6- week  open -label extension  (OLE) 
has been included to assess transition from w eekly dosing regimens for RVT-1401 and 
placebo to a every 2- week  dosing regim en (3 ad ditional doses of 340 mg ). Results from  
this trial will be use d to support progression into a larger and longer study designed to 
confirm clinical efficacy.       
3.2.2.  Dose rational e 
In MG, RVT -1401 treatment is expected to lead t o a significant r educti on in th e levels of 
pIgG  such as anti -ACh R-IgG an d anti-MuSK- IgG that are consi dered to be a primary 
driver of disease pathology.  Available evidence suggests that reduci ng the levels of p IgG 
in MG is associated with clinical benefit. For example, the use of IVIG treatment has 
been shown to r educe AChR auto antibodies by ~30% from base line and this is associated 
with clinical improvement [ Liu, 2010].  Re cently, data w ith another anti -FcRn compound 
(ARGX-113, efgartigimod), reported clinical impro vement on the Quanti tative 
Myasthenia G ravis (QMG) and  Myasthenia Gravi s-Activities o f Daily Living (MG -ADL) 
scores with an approximate 80% reduction in total IgG and 50% reduc tion in AChR- IgG 
after once weekly administration  for 4 weeks [ Howa rd, 2018].  Th ese data provide a 
target ra nge for potentially therapeutic PD effects ; however it is unknown whether there 
is a minimum threshold for pIg G reduction that t ranslates into clinical efficacy.  
RVT -1401 is designed to provid e patients w ith a treatment option that allow s home 
admini stration via subcutaneous ( SC) injection. This significantly reduces th e burden that 
an IV infusion treatment (e.g., IVIG, Soliris ® and other anti- FcRn treatments in 
development) places on patient s who wi ll be required to go t o an infusion cen ter to  
receive thei r treatment.  
 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 13 Two d osing regimens o f RVT -1401 will be assessed in double-blind phase of this study.  
Both will involve onc e weekly SC injections: 
• Dosing Regimen A -680 mg weekly for 6 w eeks, and  
• Dosing Regim en B - 340 mg weekly  for 6 w eeks   
Given that there is a practical limit on the volume that can be administered via SC 
injection, these two doses represent what can be administ ered as a single SC inject ion 
(340 mg) and two SC injections (680 mg) per week with the curr ent formulation.   
The OLE  will involve 1 dosing regimen as a single S C injection : 
• 340 mg every 2 weeks  for 6 weeks  
The OLE dose of 340 mg every  2 weeks will allow for the exploration of the effect of 
less f requent dosing of RVT -1401. This dose compr ises a less frequent regimen with a 
convenient single SC i njection . Since t he frequency of dos ing will decrease, the drug  
exposure  over the dosing interva l for subjects who were on active drug will decrease by 
approxima tely 8- 10 - fold for R egimen  A and by 1-2 fold for Regimen B. 
Expected Tr eatmen t Effect  
The propos ed dosing re gimens are expected to provide a s ustained total I gG reduction of 
approxim ately 75 -80% and 65-70% for Re gimen A and B r espectively, followi ng the 
fourth or fifth dos e. It is expected  that the nadir IgG reduction wi ll occur b y the 5th dose 
and be main tained following the sixth dose before r ising back to ba seline over the next 6 
to 8 weeks. These assum ptions are supported by preliminary PD resu lts, shown in   
Figure 1 , from  the ongoing P hase 1 clinical st udy RVT -1401-1001 (Secti on 3.2.3 ). In 
healthy participants,  4 week ly SC inj ections of 680 mg of RVT-1401 produced an 
averag e total Ig G percent red uctio n from baseline of 78%.   
For participants that enter into  the OLE , IgG levels will ri se over the 2 -week interval  
between  week 6 and the start of OLE dosing at  week 8.  The IgG levels  are expected  to 
oscillate between decreasing  and increasing o ver the next 3 doses, with trough IgG l evels 
expected to rise  by 15-25 % above the nadir levels achieved during the treatment p hase in 
the double-blind part of the study. Subjec ts who switch to  340 mg every 2 weeks from 
the placebo treatmen t are expected to  achi eve an IgG reduction of approximately 35-45 % 
after the last OLE dose . Upon completion of OLE dosing, all subject IgG levels are 
expected to return to baseline over the nex t 6-8 weeks.  
In study RVT -1401-1001, the inter-individual var iability in I gG red uctio n and PK was 
larger in the 340 mg cohort  vs. the 680 mg cohort; this  difference can be explained  by 
lower receptor oc cupancy  in the 340 mg cohort throughout the dosing int erval across all 
individuals. It is also noteworthy that, with both dos es, the v ariability in exposure 
decreased with repeat dosing.  This may indica te that full re ceptor occupancy is  not lost 
within th e dosing interval, and that with subsequent doses, mor e receptors are b eing 
occupied  or remain occupied.    
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 14 In the repeat dose 340 mg cohort, the re were some individuals who did not achieve nadir 
IgG concent ration until a fter the last dose, indicating they may have not reached steady 
state.  In contrast, most subjects in the 680 mg cohort achieved nadir concentration pri or 
to the last do se and maintained that response until after th e last dose, indicating ste ady 
state resp onse was achie ved. D ata from  this s tudy will be used to support dose selection 
in future studies.   
 
Figure 1: Mean (+/-SD) Serum IgG Reduction Following Multiple  SC Doses of RVT -
1401  
 
 
 
3.2.3.  Clinical Exp erience 
RVT -1401 has  been s tudied in  two P hase 1 clinical studie s (HL161BKN-001 and RVT-
1401-1001) des igned to assess the safety , tole rability, PK, and PD fol lowing single 
(intrav enous [IV]  and SC) and m ultipl e (SC) doses in healthy participants .  As of 
December 14 , 2018 RVT -1401 has been administered to 65 hea lthy par ticipants at  the 
following doses: 0.1 mg /kg as a 1 -hour intravenous ( IV) infusion (n=4), 100 m g as a 1 -
hour IV infu sion (n= 6), 340 mg as a 1-hour IV infusion (n=6), 0.5 mg/kg SC injection 
(n=3), 1.5 mg/k g SC  injection  (n=6), 5 mg/kg SC (n=6), 340 m g SC inj ection (n=6), 500 
mg SC injection (n =6), 765 mg SC injection (n=6). Eight participant s have received 
repeated 340 m g SC inj ections weekly f or 4 weeks and 8 participants have received 
repeated  680 mg SC injections week ly for 4 weeks  
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 15 3.2.3.1.  Safety 
See Inves tigator ’s Brochure for Details.  
RVT -1401 has been well tolerated with no Grade 3 or 4 adve rse events (AEs), a nd no 
withdraw als due to AE s. There was one SAE (Malpighian c arcinoma in left side of the 
neck ) consid ered unrelated t o study drug. 
All AEs  in subj ects receiving RVT-1401 have been reported as mild  or moderate. One 
subject who re ceived placebo  experienced sever e (Grade 3) pain fr om urinar y lithias is. 
The most frequent AE for both groups was injection site react ions (eryth ema/ and or 
swelling). Overal l, inje ction site reac tions have resolved with in a few h ours a fter dosin g; 
there were tw o exception s of mild swelling (one RV T-1401 and one pl acebo  subje ct) that 
resolved after 3 and 4 days , respectively. The frequency  of injec tion site rea ctions was 
not dose-r elated and simila r reactions were observed with placebo. Additionally, injection 
site reactions were not consistently obs erved followin g every  injection in the repeat dose 
cohorts. 
Preliminar y data suggest no subj ect who has received  RVT-1401 had clinically relevant 
changes in laboratory findings , electrocardiog rams (ECGs ), or vital sign s.   
3.2.3.2.  Pharmacokinetics  
RVT -1401 exhi bited non- linear pharmacokinet ics (PK) following single  SC 
administration  across  doses r anging fro m 0.5 mg/kg to  765 mg.  The non- linearity is 
consistent w ith RVT -1401 exhibitin g target  mediated  disposition PK.  In addit ion to  
single  dose administration,  RVT-1401 has  also been  admi nistered week ly SC for 4 weeks  
at doses of 340 and  680 mg. The  obser ved mean  concentration -time profile  follo wing the 
first and  last dose were  generally  similar, rising  to peak c oncen tration  between  2 and  3 
days after the dose an d then declin ing begin ning 4 da ys after administration  up until the 
next dose. The  rate of elimination wa s more  rapid  follo wing administration  of 340 mg  
compared  to 680 mg , indica tive of t arget  mediated  drug disposition. Acr oss both dosing 
cohorts  there was accumulatio n in the expos ure measures of Cmax  and AUC (0-168). The 
accumul ation  in Cmax  and AUC (0-168) in the 340 mg  cohort was  7 and  8.7-fold respectively  
between  the first and last dose, and 2.23 and  2.64, respectively  in the 680 mg  cohort. 
There was  large va riabili ty in Cma x and  AUC (0-168) after the first dose of 340 mg , wher eas 
there was  less va riability following first   SC dose of 680 mg , consiste nt with  what  was 
observed in  single dose data.   Overall  there was reduction in  the inter -
individual variab ility around Cma x and  AUC (0-168) after subsequent doses. Following the 
last dose in  the 680 mg  cohort, the profile  shows ch aracteristics  of target  media ted drug  
disposition, with  a linear  eliminatio n pha se from  ~96 hours to  168 hours after  the la st 
dose, at which time  the elim inatio n wa s very  rapid  from  168 hours to  336 hours post 
dose.  Exposur es increased  more than  dose prop ortionally wh en compa ring 
week  four of the 340 mg  dose to  exposures following the 680 mg  SC dose.  
 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 16 3.2.3.3.  Pharmacodynamic  
Followin g the ad ministration of s ingle SC doses  of RVT -1401, t otal I gG reduction 
increased with incr easing dose, with a maximum reduction of 47% observed after a fixed 
dose of 765 mg. The nadir for IgG reduction followin g single SC dosin g occurred 
between days 8 -15 in most individuals. Ig G serum levels  on average ret urned to within 
90% of baseline by 43 days aft er drug administration. Albumin l evels were also reduced 
from bas eline when compared to placebo showing a s imila r dose related tr end. The 
highest reduction occurring fo llowing th e 765 mg SC dose  (aver age ~14.5 %) but we re 
not cons idered to be clinically s ignificant reducti ons as all patients remained  within 
normal limits  (3.5 g/dL to 5.5 g/ dL) an d levels recover ed quickly, returning to baseline ~ 
2 weeks after nadir.  
The amount of IgG reduction  has also been assessed fo llowing weekly SC administration  
of 340 an d 680 mg of RVT -1401 or placebo for 4 we eks. Ther e were 8  subjects with data 
out to day 35, that were included in a preliminary PD  analysis for the 680 mg cohort and 
7 subjects with d ata o ut to day 4 9 that w ere included  in the analy sis for the 340 mg 
cohort. One subject only received  2 doses of 340 mg prior to withdrawing due to personal 
reasons, the ir data was not included in the preliminary PD anal ysis. There were 4 placebo 
subjects wit h data out to day 35 pooled a cross two co horts for analysis of PD endpoints.  
Figure 1 present s the mean  IgG concentration -time profiles for both we ekly SC 
administration of 340 mg and 680 mg dos es. Figure 1 shows  a reduct ion in serum IgG as 
a percent of pre- dose acr oss both 340 mg and 680 mg cohorts.  In contrast , the pla cebo 
group dem onstrated minima l changes in serum IgG as a percent of  pre-dose.  The 
reduction in serum IgG was more ra pid foll owing the 680 mg S C compared  vs 340 mg 
SC. The median IgG nadir concentra tion occu rred prior to  the last dose in the 680 mg 
cohort whereas for 340 mg , it occurred approximately 3 day s after the last dose.  The 
finding th at the 680 mg cohort achieved  nadi r concent ration following the 3rd dose and 
maintained  serum IgG reduction after th e 4th dose, indi cates a maxi mum response has 
likely bee n achieved , and t hat higher doses or more frequent dosing would yi eld little 
additiona l benefit.  This is  cons istent with data fr om othe r anti-FcRn agents in 
development t hat have observed a maximum  percent reduction in serum IgG from 
baseline of ~ 75- 80%.    
Preliminary data following the last dose acros s  both cohorts shows that IgG levels we re 
within normal range  and within 30% of the basel ine value by  5 weeks a fter the la st dose 
(average (SD) IgG concentration was 8.64 (2.73) g/L, and 8.95 (2.03) g /L for the 340 mg 
and 680 mg cohorts, re spectively). The  return towards baseline indicates  the effect is 
reversible.  The change in seru m alb umin was also assessed  following repeat SC administration of 
340 and  680 mg of RVT-1401 as compared to pooled placebo . Following both single and  
repeat dos ing RVT-1401 ser um albumin concentrations were reduced in a dose 
dependent fashion, whe reas plac ebo subje cts showed little to no cha nge in albumin 
concentrations. Wh ile there was a reduction in albumin concentrations following weekly 
dosing of 340 mg of RVT-1401, individual concentrations remained within normal limits  
(>3.5 g/dL ) for se rum a lbumin . Follow ing we ekly administr ation of 680 mg of RVT-
1401, all but 1 individual remained above 3.0 g/dL fo r the duration of dosing and most 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 17 individual s had nadir alb umin concentration prior to last do se, indicating that maximum 
albumin reduction had be en achieved . In al l individuals, albumin levels were within 
normal limits (>3. 5 g/dL) within 3-4 w eeks of the last dose for the 680 mg cohort. Across 
both cohorts, on average , individuals were within 95% of their baseline concentration 5 
weeks af ter the last dose , indicating the reversibility of th e effect of RVT -1401 on 
albumin. Th ere w ere no clinical  signs or sy mptoms reported with these transient albumin  
reductions.  
Additional in forma tion is available in the current Investigator’s Brochure (IB) .  
 
3.3. Benefi t: Risk A ssessmen t 
Summaries of find ings from both clinical and non- clinical s tudies conducte d with RVT -
1401 c an be found in the cu rrent IB.   
 
3.3.1.  Risk Assess ment  
Potential  Risk  of 
Clinica l Signific ance  
 Mitigation Strategy  
Impact  on Eligibility  Monitoring and Stopp ing Criteria OR 
Management Crit eria 
The potential for allergic 
reacti ons exists fol lowin g 
administra tion of any 
protein to human 
participants . Participant s with his tory o f significant 
allergic reactions are ineligible. Participant s will  be closely monitor ed for 
reactions for up to 1 hr  post-dose before 
they leave the cl inic.  
If during t he course of stud y drug 
administration , the parti cipant  
experiences  a drug r elated AE of Gra de 3 
(seve re) or greater severity, study drug 
administration will be stopped. 
Changes in circulating 
complement None Serum complement will be monito red 
throughout the study ( Section 8.1).  
Abnorm al val ues will be discuss ed with 
the stud y medical  monitor . 
Sustained 
hypogammaglobulinemia  The following participants will be 
ineligible:  
-Participants with a total IgG level of 
<6g/L at scre ening  
-Partici pant has ha d their spleen 
removed.  
-Participant  has a past medi cal histor y of 
primary immunodefici ency, T -cell or 
humoral, including common var iable  
immu nodefi ciency. 
-History of or known in fection with human Total IgG levels will  be monitored  
throug hout the study (Section 8.1) by an 
unblinded Medical  Monit or.   Transient 
depletion of IgG following admini stration 
of certain drugs (e.g., corticosteroids) are 
not gene rally associated with an 
increased ris k of i nfectio ns [Furst, 2008] .  
Furthermor e, available data from othe r 
FcRn ant agonis ts in development have 
not reported an increased risk of infecti on 
in short-term trials similar to RVT -1401 -
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 18 immunodeficiency vi rus (HIV), he patiti s B 
virus  (HBV), hep atitis C virus  (HCV), or 
Mycobacterium tube rculosis.  Participa nts 
must have negative te st results for HBV 
surface ant igen, HBV co re antib ody, HCV  
antibody, H IV 1 and 2 antibodies,  and a 
negative QuantiFERON® - tubercul in (TB) 
Gold test a t Screeni ng. Partici pants with 
an indeterminate QuantiFER ON® -TB 
Gold test result w ill be allowed one retest ; 
if not negative on retesting, the partic ipant 
will be excluded. 
-Absolute neutrophil count  <1500 
cells/mm3  2002. 
Sustained 
hypoalbuminemia  Inves tigator discreti on  Serum album in levels w ill be monitor ed 
throughout the study  (Section 8.1) by an 
unblinded Medical Monitor .  Treatment of 
hypoal buminemi a will be left to the 
discretion of t he investigator and decisi on 
on dos ing discussed wi th the  study 
medical monit or. 
 
 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 19 4. OBJECTIVE(S) AND ENDPOINT(S) 
Objectiv es Endpoints  
Prim ary 
To assess the s afety and tolerability of RVT -
1401 in AChR ant ibody positive MG pa tients 
over a 6-week treatment period  
 
 To examine the effects of  RVT-1401 on tot al 
IgG, IgG sub classes ( 1-4) and anti-AChR-IgG 
levels  Assessment  of safety and toler ability by  
analysis of AE  data and changes from 
baselin e in vital signs , clinical laboratory 
values, and el ectrocardiogram s  
 Change from baseline in levels  of total IgG 
and IgG subclasses ( 1-4)  
 Change from bas eline in levels of anti-AChR-
IgG  
 
 
Seconda ry 
To exa mine RVT -1401 P K following repeat 
doses in pa tients with Myas thenia Gra vis 
(MG) 
  
  
 
To measure a nti-RVT-1401 antibodie s 
following repeat  doses in  patients with MG 
and assess any p otential  impact on PK or PD  
  To examine the ef fects of RVT -1401 on the  
Quantitative Myasth enia Gravis ( QMG ) score  
 To examine the effec ts of RVT-1401 on th e 
proporti on of patients with i mprovem ent on 
the QMG sco re by ≥ 3  points from bas eline  
  To examine the effects of RVT -1401 on 
Myasthenia Gravis -Activities of Daily  Living 
score (MG-ADL)  
 To examine the effects of RVT -1401 on the 
proportion of part icipants with an  
improvement on the MG -ADL S core by ≥ 2 
points  
 PK Parameters of AUC (0 -168 h) and 
maximum concen tration ( Cmax ) after first and  
last dose  
 
Concentration of RVT -1401 pre- dose 
(Ctrough)  
  
Immunogenicity determined by cha nge from 
pre-dose in anti -RVT-1401 antibodies , 
characterization of any  anti-RVT-1401 to 
confirm neutralization  potential   
 Change from  baseline in the QMG  Score  
 
 
Proportion of participants with an improvement on the QMG score by ≥ 3 points  
from baseline  
  Change from baseline in the MG -ADL score  
 
 
 Proportion of participants with an improvement on the MG -ADL Score by ≥2 
points  
 
 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 20 To examine t he effects of RVT -1401 on the 
Myasthenia Gravis Com posite (MGC) score  
 
To examine the effects of RVT -1401 on the 
propor tion of participant s with an 
improvement on the MGC Score by  ≥3  
 To examine  the effects of RVT -1401 on the 
Myasthenia Gravis Quality of  Life (MG -
QOL15 r) score  
 Change from baseline in the MGC score  
 
 
Proportion of participants with an improvement on the MG C Score by ≥3 points  
 
 
Change from baseline in the MG -QOL15r 
score   
 
Open -Label Extension Objective: 
The objective of the OLE  is to evaluate the effect of switching to a every  2-week  dosing 
regimen of 340 mg RVT -1401 on all study endpoints.  
 
5. ST UDY DESIGN 
5.1. Overall Design  
This is a Phase 2a, randomized, double-blind, placebo -controlled  study with an OLE  
designed to investigate the safety, tol erability, PK , PD, and efficacy  of RVT -1401 (340 
mg/weekly  and 680 m g/weekly)  vs placebo  in AChR antibody posi tive MG patients . 
Following a 6-w eek double -blind, placebo- controlle d phase, all pa rticipa nts will have the 
option to enter an OLE where they w ill receive  an additional 3 doses of 340 mg RVT-
1401 every 2 weeks  for 6 week s. The study design s are illustra ted in Section 5.2.  
Safety, PK , PD, and clinical assessment s will be collected throughout the study.  Re fer to 
Section 8.1 and 8.2, Time  and Events Tables. 
Optional home visits will be offered  to collect ( at a minimum) blood samples, vital signs, 
and review adverse events  and concomitant medication s.  

 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 21 Each participant will participate in the  study for up to approximat ely 21 weeks : a 3- week  
screening period,  and a 6- week double-blind, placebo-controlled treatment p eriod.  
Participants who choose not to enroll into  the OLE  will con tinue into a 12-week follow-
up period.  Those who choose t o enroll into the OLE  will receive treatment in a 6- week 
OLE  period (3 addi tional doses, every 2 we eks), and a 6-week follow up period.  The 
study duration is the same whether a participant continues directly into the 12-week 
follow-up period or enrol ls into  the OLE .  
Randomized, Double -Blind , Placebo -Cont rolled  Phase 
Participa nts will sc reen to determine eligibility  up to 21 days  prior to first dose /baseline 
visit. Once eligibility is confirmed , participant s will be randomized on Day 1 to receive 
one of two dose regimens  or placebo for weekly SC  injections in ad dition to their 
standard of car e therapy for 6 weeks. No dose adjustments of RVT -1401 are  allowed 
during the study.  See Section 6.9 for additional information on stopping criteria.   
Following the initial dose at the Baseline Vi sit (Day 1), s tudy visits  will occur at Days 3 
and 5 and then weekly throu ghout the treatme nt period.    
After Week 6, if the participant chooses not to enroll into the OLE , they will continue 
with the 12- week follow up period. 
Transition Pha se: Option to E nroll into OL E 
Participan ts will have the option to continue with  the follow up period or enrol l into the 
OLE (described below) upon c ompletion  of the randomiz ed, double-bl ind, placebo -
control led phase of the stu dy (Week 6) .  To enrol l into the OLE, consent must be 
obtained prior to the Week 8 visit.  
The visit schedul e will be the same fo r either option as outlined in Section 5.2; two study 
visi
ts will occur at Days 38 and 40, and then week ly through Week 10 and then every 2 
weeks until Week 18.  Open-Label Extension 
If the p articipant is eligible and consents to enroll into the OLE , starting at Week 8  an 
additional 3 doses of 340 mg RVT-1401 will be administered  over a 6-week period 
(every 2 weeks ) followed by a 6-week follow up pe riod.   
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 22  
5.2. Study Schematics 
Figure 2 Study Desi gn without OLE 
 
 
Figure 3 Study Design with OLE  
 
 
5.3. Treatment A rms and Duration 
In the double-blind phase of the st udy, pa rticipants w ill be randomiz ed 1:1:1 to one of the 
three blinded t reatments  illustrated in Figure 2. 
In the OLE an additional 3 doses over a 6 -week p eriod  (every 2 weeks ) will be 
administere d, illustrated in Fi gure 3. 
 

 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 23 6. PART ICIPANT POPULATION 
6.1. Type and Number of Participant s 
A sufficient number of  participant s will be enrolled to achieve approx imately 21 
evaluable par ticipa nts. En rollme nt is c ompe titive. 
In orde r to manag e the total  study enroll ment,  the Sponsor may suspend sc reening and/or 
enrolment at any s ite or study -wide at any time.  
If participant s prematurely discontinue the st udy, ad ditional replacement  partici pants may 
be enrolled a t the discretion of the Sponsor. 
Deviations from inclusion and ex clusion c riteria are not allowed because they can 
potent ially jeopardize the scientific  integrity of the study, regulatory accept ability or 
participant safety.  Therefore, adherence to th e criteria as  specified in  the protocol is 
essential.  
To de termin e participant eligibility a t screening, a single repeat of certain tests such as 
laboratory val ues, vital signs, or ECGs is allowed  at the discr etion of the Principal 
Inves tigato r. 
 
6.2. Inclusion Criteria  
A par ticipant wil l be eligib le for inclu sion in this study only if all of the foll owin g criteria 
apply: 
1. Male or  female ≥  18 y ears of age.  
2. Myasthenia Gravis Foundation of America ( MGFA ) Cla ss II-IVa and likely not in 
need of a respirat or for the  durat ion of the study as judge d by the Investigator. 
3. Positive ser ologi c test f or anti- AChR an tibodies at the scr eening vis it and  at leas t 1 
of the following:  
a. History of abnormal neuromuscular transmi ssion test  demonstrated by sing le-
fiber-elect romyo graph y or repetitive nerve stimulation OR 
b. History of positive edrophonium chloride t est OR  
c. Particip ant has demonstrated improvement in MG sign s on oral cholinester ase 
inhibitors as assessed by the treating  phys ician.   
4. QMG score ≥12 at Screeni ng and  Baselin e.  
5. Stable dose of MG treatment prior to randomization. F or p articipant s receiving A ZA, 
other non- steroidal immunosuppressive agents , steroids, and/or cholinestera se 
inhibitors as concomitant medicati ons the fol lowing conditions will apply: 
a. AZA: treatment initiat ed at least 12 months ago a nd no dose changes in the last 
6 months be fore Screening.  
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 24 b. Other immunosuppressive treatment (e .g., methotrexate, cyclosporine, 
mycopheno late mofetil, and cyclophosphamide) initiated at le ast 6 months ago 
and no dose changes in th e last 3 months before Scre ening.  
c. Stable dose of s teroid treatme nt at least  6 weeks  before Baseline. 
d. Cholinest erase in hibitors: stable d ose for > 1 week before Screeni ng. Note: 
cholinesterase inhibitors mu st be held for at least 12 hours consistent w ith the 
revised manual for the QMG  test as recommended by the MGFA, bef ore the 
QMG a nd MGC assessments.      
6. A female particip ant is eligible to  participate if she is of:  
a. Non-childbearing potential defined as pre- meno pausal females with a 
documented bilater al tubal ligation, bilateral oophorectomy (removal of the 
ovaries) or h ysterectomy; hysteroscopic sterilization, or postmenopausal defined 
as 12 months of spontaneous amenor rhea [in questionable cases a blood sa mple 
with simultaneous follicle stimulating h ormone (FSH) in the post-menopausa l 
range is confirmatory ].  
b. Child -bearing potenti al and agree s to use one of the contracepti on methods 
listed in Section 6.6.1 for an  appropriate period of time (as determined by  the 
product label or Principal In vestigator ) prior to the start of dosi ng to suffic iently 
minimi ze the risk o f pregnancy at that point.  Female participant s must agr ee to 
use contraception until 90 days after t he last dose of study treatment. 
7. Male partici pants must ag ree to use one of the contracept ion methods listed in 
Section 6.6.1.  Th is criterion must be followed fro m the time  of the first dose of 
study treatment until 90 days after  the last dose of study treatme nt. 
8. Willing and c apable of gi ving writte n informed consent, which i ncludes compliance 
with the requiremen ts and restrict ions lis ted in the consent form. 
 
6.3. Exclusi on Criteria 
A participant  will not be eligible for  inclusion in this study if any of the follow ing criteria 
apply: 
1. Use of ri tuxi mab, be limumab, ecu lizumab or any monoclonal antibody/Fc-fusion 
biologic for im munomodulation within 6 months pr ior to first dosing.   
2. Use of t acrolimus  within 1 week of first dose and throughout the tr eatment period.  
3. Immun oglobulins given by SC , IV (IVIG), or in tramuscular route, or 
plasmaph eresis/pl asma exchange (PE) within 4 weeks before Screening.  
4. Thyme ctomy performed < 12 months prior to screening.  
5. Total IgG level < 6 g/L (a t screening ). 
6. Absolute neutrophil count <1500 cells/mm3(at screenin g). 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 25 7. Participant  has any laborat ory abnormalit y (at screeni ng) that, in the opinion of the 
investigator, is clinically significant, has not resolve d at baseline, and could 
jeopardize or would compr omis e the pa rticipant's ability to  participate in this  study. 
8. Have k nown autoim mune disease other than MG that would i nterfere with the course 
and conduct of the study (such as uncontrolled thyroid di sease) . 
9. Medical his tory of prima ry immunodeficiency, T-c ell or humoral, including common 
variab le immun odeficiency.  
10. Have an active infection, a rec ent serious infec tion (i.e., requiring injectable 
antimicrobial therapy or hospitalization) within the  8 week s prior to Screenin g. 
11. History of or known infection with  hum an immunodeficiency virus (HIV ), hepatitis 
B virus (HBV), hepati tis C virus  (HCV), or M ycobacterium t uberculosis. 
Participant s must have negative test results for HBV surf ace antigen, HBV core 
antibody, HCV antibody, HI V 1 and 2 antibodies, and a negative Quanti FERON® -
TB Gold test at S creen ing. Par ticipants with an ind eterminate QuantiFERON® -TB 
Gold test res ult will b e allowed one retest; if not negative on retesting, the participant  
will be  excluded.  
12. Participant  has any clinically  significant his tory o f allergic  conditions (including 
drug a llergies , anaphylactic reacti ons), that would in the opinion of the I nvestigato r 
or Medical Monitor, contraindicates their participation . 
13. Participant  has any medical condition (acu te or chronic  illness) or psychia tric 
condition  that, in the opinion of the investig ator, could jeopardize or would 
compromise t he participant 's ability to  participate in this study  
14. Body Mass Index (BMI) at Screening ≥ 35 kg/m2. 
15. Use of i nvestigational drug within 3 months or 5 half- lives of the drug (w hichever is 
longer) before Screening.  
16. Currently participating or has participated in another MG c linical study within 28 
days prior to  signing the informed consent form.  
17. Participant  has received a live vaccinatio n within 8 weeks prior to the Baselin e Visi t; 
or intends to have a live vaccination during the course of the study or within 7 weeks 
following the final dose of study treatment.  
18. Participant  has  received a transfusion of any blood or blood products within 60 days 
or donated plasma within 7  days prior to Day baseline . 
19. History of sensitivity to any of the study treatment s, or components thereof or a 
history of drug or other alle rgy that, in the opinion of the Investigator or Medical 
Monitor , contraindicates th eir participation.  
20. Pregnant  or lactat ing fe males as determined by positive serum or urine human 
chorionic gonadotropin test at screening o r baseline. 
21. Participant  has had the ir spleen removed. 
22. QTcF interval >4 50 milliseconds for males  and >4 70 milliseconds for females  at 
Screening (a  single re peat i s allowed for eligibility determination ).  QTc F >480 msec 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 26 in pa rticipants with Bundle Branch Block . 
 
6.4. Eligibility for the OLE  
Participants who complete the 6-w eek, randomized, double-blind treatment phase are 
eligible to parti cipate in the OLE . 
6.5. Other Eligibility Criteria Considerations 
To assess any potential impact on participant  eligibility with regard to safety, the 
Principal Inve stigator mu st refer to the followin g document(s) for detailed information 
regarding wa rnings , precau tions, contraindications, AEs , and other significant data 
pertaining to the investigational product(s) being used in this study: 
RVT -1401 Investigator’s Bro chure 
 
6.6. Scr eening/Baseline Failures 
Screen failures are defined as participant s who cons ent to participate in the clinical  trial 
but are never subsequently randomized.  A minimal set of screen failure information is 
required including demography, s creen f ailure detai ls, el igibility c riteria,  and any SAE s.  
Screen failure data will be recorded with in the electronic Case R eport Form ( eCRF). 
 
6.7. Lifestyle Restrictions 
6.7.1.  Contraception  
Femal e participants of childbearing potential must no t become pregnant and so must be 
sexual ly inactive by abstinence or agree to use a highly effective method of contra cepti on 
(i.e., pregnancy rate of le ss than 1% per year). 
Abstinence  
Sexual inactivity by abs tinence must be consistent with the preferred and usual lifestyle 
of the part icipant. Pe riodic abstinence (e.g.,  calendar, ovulation, symptothermal, 
postovulations metho ds) and withdrawal are not acce ptable metho ds of contraception. 
Contraceptive Methods w ith a Failure Rate of <1% 
• Combined hormonal cont raception associated with inh ibition of ovula tion (oral, 
intravaginal, transdermal).  
• Progestogen -only hormonal con tracep tion associated with inhi bition of ovul ation 
(oral, injectable, implantable) . 
• Intrauter ine device (IUD) or intrauterine system (IUS) that meets the <1% failure 
rate a s stat ed in th e product label . 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 27 • Male partner sterilization (vasectomy with docu mentat ion of azoospermia) prior 
to the fem ale parti cipant's entry into the study, and this male is the sole partner for 
that participant . For this definition, “documented” refe rs to th e outcom e of the 
investigator's/designee’s medical examination of the pa rticip ant or review of the 
participan t's medical hi story for study eligibility, as obtained via a ve rbal 
interview with the participant  or from the  participant ’s medical record s.  
 
• Female participants and female partners of male study participants using a 
hormona l con traceptive must also use a bar rier meth od (i.e., condom or occlusive 
cap [diaphragm or cervical/vault caps]) and should have been stable on their 
hormonal contraceptive treat ment for at least 4 weeks  before Screening.  
• Sterilized male participan ts who  have had vasectomy with documented 
azoosperm ia post procedure can be included.  
• Non-steriliz ed male participant s who are sexually active with a female partner of 
childbe aring po tential must use effective method of double barrier contraception. 
Male partic ipants practicing true sexual abstin ence (when this  is in line with the 
preferred and usual li festyle of the participant) can be included.  In addition, male 
participant s mu st be ad vised not to donate sperm during this period from signing 
of Informed Consent Form  (ICF), throughout the duratio n of the stud y, and for 90 
days after the last administra tion of study drug. 
These allowed methods of contraception are only effective when us ed consistently,  
correctly and in accordance with the product label. The invest igato r is responsible for 
ensuring p articipa nts understand how to properly use these methods of contraception.  
Participant s must be complete ly informed of the unknown ri sks of pre gnancy and agree 
not to become pregnant during the time they are participati ng in this study. If there is a ny 
question th at a pa rticipant will not be reliable in the use  of appropriate contraceptive 
methods, they should not be entered into the stud y. 
 
6.8. Withdrawal Criteria 
6.8.1.  Reasons f or Withdrawal   
A Principal Investigator  may discontinue/withdraw a study participa nt’s participation  in 
the study if any of the following criter ia apply : 
• Any clinical AE, laboratory abnormality, or other medical condition or situ ation 
occurs such that continued participation in the study would not be in th e best  
interest of the particip ant. 
• Participa nt pre gnancy  
• Significant protocol violation  
• Beh
avioral or administrative reason  
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 28 • Participant  requ est to discontinue /withdraw c onsent for any  reason .  It is 
impor tant to document whether the withdrawal of co nsent i s primarily due to an 
AE, lack  of efficacy, or o ther reason . 
• Discontinuation of the study at the request of the Sponsor , regulatory agency o r an 
Institutional R eview Boa rd / Ind ependent Ethics Committee  
• Stopping criteria, as noted in Section 6.9 
If a partic ipant meets a withdrawal criterion  during treatment, an Early T ermination 
visit will be required ( Section 6.7.2). 
 
6.8.2.  Participant Withdrawal Procedures 
If a participant is prematurely discontinued from the study, the Pr incipal Investigator  
must make every effort to perform an Early Termination Visit per Section 8.1 and 
Section 8.2, Tim e and Events Tables an d document the primary reason f or withdrawal.  
Should a participant  fail to attend the clinic for a req uired study visit, the site should 
attempt to contact the participant  and re-schedule the missed visit as soon as possible.  
The site  should also counsel the participant  on the i mportance of maintain ing the 
assigned visit schedule and a scert ain whether o r not the participant  wishes to and/or 
should continue in the study based on previous non- compliance.   In cases where the 
partici pant does not return for the rescheduled visit or c annot be reached to reschedule the 
missed visit, the site should make ev ery effort to regain contact with the participan t (3 
documented telephone calls and if necessary  a certified letter to the pa rticipan t’s last 
known mailing addr ess) so that they can ap propria tely be withdr awn from the study  with 
a primary reason of “Lost t o Follow-up”. 
 
6.9. Stopping Criteria for Individual Participants 
6.9.1.  Liver Chemistry Stopping Criteria  
Hepatic enzymes will be monito red in ac cordanc e with FDA drug -induced liver injury 
guidel ines [FDA , 2009]. 
If the following liv er test abnorm alitie s develop, Study Treatment should be withheld 
immediately with appropriate clinical follow -up (including repeat laborat ory test s, unt il a 
participant ’s laboratory profile has returned to normal/baseline status), and the event 
reported as a SAE : 
• Alanine aminotr ansf erase ( ALT ) or aspartate aminotran sferase ( AST )> 8 x 
upper limit of normal ( ULN ); or 
• ALT or AST  > 5 x ULN and persists f or mo re than 2 weeks; or  
• ALT or AST > 3  x ULN and total bilirubin > 2  x ULN  or international 
normalized ratio ( INR) >  1.5 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 29 • ALT or A ST > 3 x ULN with appearance of fatigue,  nausea, vomiting, right 
upper quadrant pain or tenderness, f ever, rash and/or eosinophilia  (> 5%).  
Rechallenge may be considered if an alternative cause for the abnormal liver tests (ALT, 
AST, tota l bilirubin) is di scovered and the laboratory abnormalities resolve to normal or 
baseline values.   The Inv estigator and  sponsor must di scuss an d agree with any decision 
to rechallenge.  
Rechallen ge should not occur when the etiology of the liver test abnor malitie s is 
considered possibly drug induced. 
 
6.9.2.  Criteria for  Permanent Discontinuation of Study Treatment in 
Association with Liver Test Abnormal ities 
Study treatment should be discontinued perman ently if all of the follo wing 4  criteria are 
met (i.e., potent ial severe drug- induced liver injury/Hy’s law case):  
1. Total  bilirubin increases to > 2 x ULN or INR > 1.5; AND 
2. AST or AL T increases to ≥  3 x ULN;  AND  
3. Alkaline phosphatase value does not reach 2 x U LN; A ND 
4. No alternative cause explains the combination of the above laboratory 
abnormalities; important alternative causes include, but are not limited to the followin g: 
• Hepatobili ary tract disease;  
• Viral hepatitis ( e.g., hepatitis A/B/C/D/E, Epstein -Barr virus); 
• Exposure to hepatotoxic agents/drugs or hepatotoxins, including herbal and dietary supplements, plants, and mushrooms; 
• Alcoholic hepatitis; 
• Non-alcoholic steat ohepatitis; o r 
• Autoimmune hepatitis.  
If an alternative cause for hepatotoxicity is ident ified, then it should be determined (based 
on the severity of the hepatotoxicity or event) whether Study Treatment should be withheld or permanently discontinued as appropr iate for the safety of the partici pant. 
 
6.9.3.  QTc Withdrawal Criteria  
• QTc prolongation de fined as QTcF >500 ms, or an increase of QTcF >60 ms above 
baseline on the 12- lead ECG, confirmed (persistent for >5  minutes) on repeated 12-
lead ECGs  
 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 30 6.9.4.  Albumin Monitori ng C riteria 

 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 31 6.10.  Toxicity Management Criteria  
6.10.1.  Toxicity Management Criteria (AEs, Cardiovascular, and Site 
Reactions)  
The severity of each AE  will be gr aded and managed  accordin g to the criteria in  Table 1. 
Table 1 Criteria for Determining the Gra de/Severity of Adverse Event Terms 
Grade Criteria  
1/Mild  Asymptomatic or mild symptoms, clinical or  diagnostic  observations 
only; intervention not indicated  
2/Moderate  Limiting age -appropriate instrumental activities of daily living ; 
minimal, loc al, or n oninvasive intervention as indicated  
3/Severe or medically significant  Not immediately life -threate ning; hospi talization or prolo ngation of 
hospitalization indicated; disabling; limiting self-care activities of 
daily living, intervention as indicated  
4/Life-threatening  Life threatening consequences; urgent intervention indicated  
5/Death  Death related to adverse event  
 
Injection  Site Reactions 
Injection site evaluations will be made by  clinical staff following administra tion of RVT -
1401 and placebo as described below .  Additional details related to the specific injection 
site location will be included within a st udy specific manual . If an injection  site reaction 
is observed, a physici an will characterize and document the reaction as an AE. Review  of 
the injection  site will continue until the AE is resolved. Symptomatic treatment (e.g. 
antihistamines, NSAIDs , IV fl uids) may be p rovided for any injection site reactions based 
on the discr etion of the Investigator.  
The in jection  sites will be  monitored for pain, tenderness, erythema and swelling. Each 
injection  site reaction will be categorized using the in tensity gra ding s chem e presented in  
Table 2. 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 32 Table 2 Criteria for Determining the Grade/Severity  of Injection Site 
Reactions  
Grade Criteria  
1/Mild  Tenderness with or without associ ated symptoms (e.g., warmth , 
erythem a, itchin g) 
2/Moderate  Pain; lipod ystrophy; edema; phlebitis  
3/Severe or me dically signifi cant Ulceration or necrosis ; severe tissue damage; operative 
intervention indicated  
4/Life -threatening  Life threatening consequences; urgent intervention indicated  
5/Death  Death 
Common T erminology  Criteria for Adverse Events (CTCAE) Ver sion 4. 0 Publishe d: May 28, 2009 (v4.03: 
June 14, 2010) . 
 
6.10.2.  Other Management Criteria  
For an individual study participant, medical monitor notifica tion criter ia include, but are 
not limited to: 
• Severe signs o r symptoms,  or significant changes in any of the s afety a ssessments, 
that put the safety of the individual at r isk (e.g. laboratory tests or vital signs, etc.) as 
judged by the Investigator.  
 
6.11.  Participant and Study Completion 
A completed part icipant  is one who has com pleted all phases of the study includ ing the 
follow-up visits. 
The end of the study is defined as the last participant ’s last visit.  
 
7. STUDY TREATMENT  
7.1. Investigational Product and Other Study Trea tment 
The term  study trea tmen t is used throughout the protocol to describe RVT -1401 or 
placebo .   
To m aintain the stu dy blind within the double-blind phase of the study, a ll participant s 
will receive two i njections (2 ml volume each) by an unblinded designee (Section 7.6) ; 
partici pants receivin g the 680 mg dose will receive two inje ctions of RVT -1401, while 
participant s receiving the 340 mg dose w ill receive one injection with RVT -1401 and one 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 33 placebo injection .  Participant s receiving placebo w ill receive two  injections  of placebo .  
The blinded syri nges w ill be numbered so that any in jection site reactio n can be assigned 
to a specific syringe number and medication  #.   
The OLE  is open- label .  Each participant will receive 3 additional doses of RVT-1401, 
once every 2 weeks , as a single 340 mg injection  over a 6 -week period.  
Double -Blind : Investigational Product  
Study Treatment Name : RVT-1401  Placebo  
Suppl ier: 
Dosage formulat ion: Sterile solution for injectio n.  Sterile s olution for in jectio n.  
Unit dose 
strength(s)/ Dosage level(s):  340 mg : 2mL RVT-1401  in one 
syringe and 2m Ls placebo in the 
second syringe  for a total of 4 m L 
 
680 m g: 2 mL RVT-1401 in two 
syringes for a total  of 4 mL 2 mL placebo in two 
syringe s for a total  of 4 m L 
 
 
Route of Administrati on  SC injec tion 
Dosing ins tructions:  The detailed methods are ind icated in th e Pharmacy M anual.  
Participants will be closely monitored for reactions for up to 1 hr 
post-dose befo re they leave the clinic.  
Dose Preparati on The prepara tion p rocedure and ex piry details  will be include d in 
the Pharmacy manual /product label . 
 
OLE: Investigational Product  
Study Treatment Name : RVT-1401  
Suppl ier: 
Dosage formulation:  Sterile  solution for injectio n.  
Unit dose 
strength(s)/ Dosage level(s):  340 mg : 2mL RVT-1401  in one syringe  
 
Route of Administration  SC injec tion 
Dosing ins tructions:  The detailed methods are ind icated in th e Pharmacy M anual.  
Partic ipants will be closely moni tored for reactions for up to 1 hr 
post-dose befo re they leave the clinic.  
Dose Preparati on The preparation procedure and expiry details  will be include d in 
the Pharmacy manual /product label . 
 
 
 

 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 34 7.2. Treatment Assignment 
Randomization within the double-blind phase will occu r centrally usin g an interactive  
web response system (I WRS) using central  randomization.  P articipant s will be assigned 
in accordance with  the randomization schedule, prepared prior to the start of the study. 
The O LE is open- label.  
 
7.3. Blinding 
This will be a double-blind study. The inve stigator and study si te will also rem ain blinded 
to the IgG, albumin, total protein , alkaline phosphatase (ALP), and anti-AChR antibody 
data post s creening as this  could potentially unblind them.  An unblinded Medical 
Monitor will review this lab  data on an ongoing basis for sa fety.  In order to maintain the 
blind of which treatment subjects received during the double-blind phase of the study, 
these labs will continue to be blinded to th e investi gator and study site in the OLE.  
  The f ollowing will apply throughout the stud y: 
• The Investigator or t reating physician may unblind a participant ’s treatment 
assignm ent only in the case of an emergency  OR in the event of a seri ous medical 
condition when knowl edge of the study treatment is essen tial for the appropriate 
clinical manag ement  or welfare of the participant  as judged by the Investigator. 
Emer gency unblinding will be available via the IW RS or via the unblinded 
pharmacis t.  
• The Inves tigator should m ake ev ery effort to first  conta ct the M edical Monitor or 
appropriate study personne l to discuss options before unblinding the participant’s 
treatment  assignment.  
• If the Medical Monitor is  not contacted before the unblinding, t he Investigat or must 
notify t he Sponsor as soon as pos sible after un blinding.  
• The date and reason for the unblinding (the event or  condition which led to the 
unblinding) must be fully documented in the e CRF  
A participant  will be withdrawn if the particip ant’s treatme nt code is unblinded b y the 
Investigat or or tre ating ph ysician.   
The Sponsor or their designe e may  unblind the treatm ent assignment for any participant 
with a SAE. If the SAE requires that an expedited regulatory report be sent to one or 
more  regulatory a gencie s, a copy of the report, identif ying the particip ant’s treatment 
assignment, may be sent  to Investigator in acco rdance with local regulations. 
 
7.4. Packaging and  Labeling  
RVT -1401 will be supplied to the study site as a sterile li quid formul ation with a nomina l 
fill of at l east 1 mL in Nuova Om pi 2R clear glass v ials with a flip -off cap. The solution 
is clear to slightly  yellow, essentially free of visible particles,  for SC  administration.  

 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 35 Placebo wi
ll be pro vided as a sterile liquid  formulation with at least a  1 mL fill in Nuova 
Ompi 2R clear g lass vials with a flip -off cap. The solution is cl ear, essentially free of  
visible particles,  for SC administration.
 
Doses will be  prepared by the unblinded pharmacist  or designee with a labe l that includ es 
at a minimum the st udy number, partici pant number, medication  number and vial 
number. Doses are ad minister ed to participant s by pre-identified unblinded clinic staff  or 
design ee.  
See Ph armacy Manual for exact instructions on dose preparation. 
All labels will meet  all local appli cable requiremen ts and Annex 13 of Good 
Manufacturing Practices: Manufactu re of inves tigational medicinal p roducts (July 2010) 
and/or other local regulations as a pplicable.  
 
7.5. Preparation/Handling/Storage/Accountability 
A descr iption of the m ethods and m aterials required for pre parati on will b e detailed in the 
pharmacy manu al. 
• Only participants enrolled in the study m ay recei ve study tre atment and only 
authorized site staff may prepare, handle, supply or administer study treatme nt.  All 
study treatme nts must  be stored in a s ecure environmen tally controlled and 
monitored (manual or automated) area in accordance with the labelle d storage 
conditions with access limite d to the Investigator and authorized site staff.  
• For the double-blind phase of the study, t he Unblinded P harmaci st or desig nee is 
responsibl e for study treatment accountabil ity, reconcil iation, and record 
maintenance (i.e. receipt, reconciliation an d final disposition records).   
• Under normal conditions of handling and administra tion, st udy trea tment is not 
expected  to pose sig nificant s afety risks  to site staff .  In the c ase of unintentional 
occupat ional exposure notify the unblinded monitor, Medica l Monito r and/or the 
Sponsor study contact. 
• A Material Safety Data Sheet (MSDS)/eq uivalent document describing o ccupationa l 
hazard s and reco mmended handling precautions either w ill be provided to the 
Inves tigator, where this is required by local laws, or i s available upon request from 
the Sponsor. 
 
7.6. Compliance with Study Treatment Administration 
For the double-blind phase of the study only, the individual dose for a participant is prepared  by an unblinded P harmacist , licensed  Pharmacy Technic ian, or designee. T he 

 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 36 preparation of the dose w ill be  reviewed and  conf irmed by a seco nd unblinded member  of 
the study site st aff.  
For the double-blind phase of the study only, t he IP will b e administer ed by an  unblinded 
design ee. For the double-blind phase and the OLE , the date and tim e of each dos e 
administe red along wi th the location of e ach inject ion ide ntifie d by syringe number, w ill 
be recorded in the source documents.  The location/syring e number and study pa rticipant  
identification will be confirmed at  the time of dosing by a member of the s tudy site st aff 
(blinded to stu dy treatment)  other th an the person administering the stud y drug .  
 
7.7. Treatment of Study Treatment Overdose 
The Sponsor does not recommend spec ific treat ment fo r an overdose.  
In the event of an overdose the Invest igator or trea ting physician should: 
• contact the Medical  Monitor immediat ely, 
• closely monitor the pa rticipant  for AEs/SAEs  and laboratory abnormalities . 
• obtain a pl asma sample for PK an alysis with in 2 da ys from th e date of the las t 
dose of study treatment if  reques ted by the Medical Monitor (de termined on a 
case-by-case basis)  
• document the quantity of the excess dose as well as the du ration of the overdosing 
in the e CRF  
Decisions regardin g dose inte rrupti ons or modifications will b e made by the Investigator 
in consul tation with the Medical Monit or bas ed on the cli nical  eval uatio n of the 
participant . 
 
7.8. Treatment After the End of the Study 
Participant s will not receive any additional treatme nt with the study trea tment from the 
Sponsor after completion of the study becau se the long- term safety and ef ficacy of RV T-
1401 have not been es tablished.  
The Principal I nvestigator  is responsible for ensuring that consideration has been given to 
the post- study care of the  participa nt’s medic al cond ition, whether or not the Sp onsor is 
providing specific post-stud y treatment.  
 
 Immunovant Sciences GmbH  RVT-1401- 2002 , Version 3.0 
  
Confidential 37 7.9. Concomitant Med ications and Non-Drug Therapies 
7.9.1.  Permitted Medications  and Non- Drug Therapies  
Any concomitant me dication should be record ed in the study records, including the dos es 
administered, the dates  and time s of administration and the re ason for adm inistration. 
Refer to S ection 6.2 and  Section 6.3 in the study inclusion and ex clusion criteria fo r 
perm itted standard of care MG treatments.  
7.9.2.  Prohibi ted Med ications and Non- Drug Therapie s 
Refer to t he ex clusion criteria ( Section 6.3) and the SRM for a list of prohibited 
medications.  
 
8. STUDY  ASSESSMENTS A ND PROCEDURES  
Protocol waiv ers or exemptions are not allowed  with the ex ception of i mmediate safety 
concerns.   Therefore,  adhere nce t o the study design requirements, including those 
specified in the Time and Events Tables, a re essential and required for s tudy conduct.  
This sect ion lists the procedure s and parameters of each p lanned s tudy assessment.  The 
exact tim ing of each assessment is li sted i n the Time and Events Tables, S ection 8.1 and 
Section 8.2.  
The following points must be noted:  
• The Institutional Revi ew Boa rd (IRB)/Independent Ethics Commi ttee (I EC) will 
be informe d of any s afety issues that requir e alterati on of the safety monitoring 
scheme or amendment of the Informed Consen t Form .  
• The total blood volume collected w ill be specified with in the ICF. 
 
  Immu novant Sciences Gm bH RVT-1401- 2002 , Version 3.0 
   
Confide ntial 38 8.1. Time and Events Table (12-week follow-up without OLE) 
 
Screening1 Treatment P eriod 
Week 1  
(Days)  Treatment  Period 
Weekly Vis it 
(Weeks) Treat ment Period 
Week 6  
 (Days)  
 Follow -up Period  
Weekly Visit 
(Weeks)  Early 
Withdrawal 
Visit  
Study Timepoint 
(Weeks ) Within 21 
Days  Day 1 
(Baseline)   
Day 
3  
Day 
5  
2 
(Day 
8) 3 
(Day 
15) 4 
(Day 
22) 5 
(Day 29) 6 
(Day 
36) Day 
38 Day 
40 7 8 9 10 12 14 16 18  
Time Window 
(days)     
+1 
day  
+1 
day  
+/-1 
day  
+/-1 
day  
+/-1 
day  
+/-1 
day +/-1 
day +1 
day +1 
day  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/- 
2 
days  
Informed consent  X                    
Inclusi on/exc lusion  
criteria  X X                   
Demo graphics and 
medical hist ory X                    
Height  X                    
Body weight  X X                   
Complete physic al 
examination  X X                   
Brief physical 
examination                    X X 
Vital signs2 X X X X X X X X X X X X X X X X X X X X 
12-lead 
Electrocardiogram2 X X   X  X  X          X X 
Pregnancy t est3 
(females)  X X   X X X X X          X X 
QuantiFE RON®-TB 
Gold  X                    
Viral Serology  X                    
Urinal ysis2 X X   X X X X X   X       X X 
Blood c hemistry  
and hematology2 X X   X X X X X   X       X X 
Serum complement 
(CH50, C 3)2  X   X X X X X   X       X X 
  Immu novant Sciences Gm bH RVT-1401- 2002 , Version 3.0 
   
Confide ntial 39  
Screening1 Treatment P eriod 
Week 1  
(Days)  Treatment  Period 
Weekly Vis it 
(Weeks) Treat ment Period 
Week 6  
 (Days)  
 Follow -up Period  
Weekly Visit 
(Weeks)  Early 
Withdrawal 
Visit  
Study Timepoint 
(Weeks ) Within 21 
Days  Day 1 
(Baseline)   
Day 
3  
Day 
5  
2 
(Day 
8) 3 
(Day 
15) 4 
(Day 
22) 5 
(Day 29) 6 
(Day 
36) Day 
38 Day 
40 7 8 9 10 12 14 16 18  
Time Window 
(days)     
+1 
day  
+1 
day  
+/-1 
day  
+/-1 
day  
+/-1 
day  
+/-1 
day +/-1 
day +1 
day +1 
day  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/- 
2 
days  
Immunoglobulin s 
(IgM, IgA)2  X    X   X   X X X     X X 
RVT-1401 PK 
sampling2  X X X X X X X X X X X X       X 
Total IgG2 X X X X X X X X X X X X X X X X X X X X 
Immuno globins  
(IgG subclasses)2  X X X X X X  X X X X    X     
Anti- RVT-
1401antibody2, 4  X    X      X    X   X X 
Nab Assessment2  X    X      X    X   X X 
anti-AChR 
antibody2 X X X X X X X X X X X X X X X X X X X X 
Drug admin istration   X   X X X X X            
Injection site 
reactions5  X   X X X X X            
MG-ADL6, 7  X   X X X X X   X X  X X   X X 
Quantitative 
Myasthenia Gravis 
(QMG) Sco re6, 7 X X   
X X X X X   X X  X X   X X 

  Immu novant Sciences Gm bH RVT-1401- 2002 , Version 3.0 
   
Confide ntial 40  
Screening1 Treatment P eriod 
Week 1  
(Days)  Treatment  Period 
Weekly Vis it 
(Weeks) Treat ment Period 
Week 6  
 (Days)  
 Follow -up Period  
Weekly Visit 
(Weeks)  Early 
Withdrawal 
Visit  
Study Timepoint 
(Weeks ) Within 21 
Days  Day 1 
(Baseline)   
Day 
3  
Day 
5  
2 
(Day 
8) 3 
(Day 
15) 4 
(Day 
22) 5 
(Day 29) 6 
(Day 
36) Day 
38 Day 
40 7 8 9 10 12 14 16 18  
Time Window 
(days)     
+1 
day  
+1 
day  
+/-1 
day  
+/-1 
day  
+/-1 
day  
+/-1 
day +/-1 
day +1 
day +1 
day  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/- 
2 
days  
Myasth enia Gravis 
Composite ( MGC) 
Score6, 7  X   
X X X X X   X X  X X   X X 
Myast henia Gravis 
Quality  of Life (MG -
QOL15 r) Score6, 7  X   
  X     X   X X   X X 
Satisfaction 
Questionnaire             X        X 
Adver se events  X X X X X X X X X X X X X X X X X X X X 
Concom itant 
medica tion X X X X X X X X X X X X X X X X X X X X 
1. Screening  can take place over mul tiple days to ensure participant s withhold cholinesterase inhibitors for at least 12 hours prior to the QMG and MGC assessm ents.  
2. Vitals , ECG  and blood dr aws for safe ty, PK, and PD  assessment will be collec ted pre- dose on dosing days  where specified.  
3. Pregna ncy tests will be collected  pre-dose (via urine dipstick) on dosing days where specified. Serum preg nanc y tests should be c ollected at sc reenin g, week 18, and early withdrawal . 
4. Participant s posi tive for an ti- RVT-1401 antib ody at Week 18 will be requested to return at approximately 6, 9 , and 12 months post -dose for additional samples  or until  their result is  no longer positive . However, for 
purposes of saf ety follow -up and databas e lock participation ends at the Week 18 visit.  
5. Local in jectio n site reaction s will be assessed at approxima tely 10 minutes post dose. 
6. MG assessments will be assesse d pre- dose when collected on dosi ng days 
7. Subjects sho uld be instr ucted to withhold choline sterase inhibitors for at l east 12 hours prio r to the QMG  and M GC assessments.  
 
 
 
  Immu novant Sciences Gm bH RVT-1401- 2002 , Version 3.0 
   
Confide ntial 43  
Screening1 Treatment Period 
Week 1  
(Days)  Treatment  Period 
Weekly Vis it 
(Weeks) Treatment Period 
Week 6  
 (Days)  
 OLE and Follow -up Period  
Weekly Visit  
(Weeks)  Early 
Withdrawal 
Visit  
Study Timepoint 
(Weeks ) Within 21 
Days  Day 1 
(Baseline)   
Day 
3  
Day 
5  
2 
(Day 
8) 3 
(Day 
15) 4 
(Day 
22) 5 
(Day 29) 6 
(Day 
36) Day 
38 Day 
40 7 8 9 10 12 14 16 18  
Time Window 
(days)    
+1 
day  
+1 
day  
+/-1 
day  
+/-1 
day  
+/-1 
day  
+/-1 
day +/-1 
day +1 
day +1 
day  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/-2 
days  
+/- 
2 
days  
Myasthenia Gravis 
Composite ( MGC) 
Score 8,9  X   
X X X X X   X X  X X   X X 
Myast henia Gravis 
Quality  of Life (MG -
QOL15 r) Score 8,9  X   
  X     X   X X   X X 
Satisfaction 
Questionnaire             X        X 
Adver se events  X X X X X X X X X X X X X X X X X X X X 
Concom itant 
medication X X X X X X X X X X X X X X X X X X X X 
1. Screening  can take place over mul tiple days to ensure participant s withhold cholinesterase inhibitors for at least 12 hours prio r to the QMG and MGC assessm ents.  
2. Consen t for enrollment  into the OLE must  occur  prior to Week 8.  
3. Participants wh o complete the 6- week, randomized, double- blind treatment phase are eligible to participate in the OLE   
4. Vitals , ECG  and blood draws for safet y, PK, and PD  assessment will be col lected pre- dose on dosing days  where specifie d. 
5. Pregna ncy tests will be collec ted pre-dose (via urine dipstick) on dosing days wh ere specified.  Serum preg nanc y tests should be c ollected at sc reening, week 18, and early withdrawal . 
6. Participant s posi tive for an ti- RVT-1401 antib ody at Week 18 will be requested to return at approximate ly 6, 9, and 12 months post -dose for additional s amples  or until their result is  no longer positive . However, for 
purposes of safety follow -up and databas e lock participati on ends  at the Week 18 visit.  
7. Local in jectio n site reaction s will be assessed at approx imately 10 minutes post dose. 
8. MG assessments will be assessed pre- dose when collected on dosi ng days.  
9. Subjects should be instructed to withhold choline sterase inhibitors for at l east 12 hours prio r to the QMG  and MGC assessments.  
 
 
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 44 8.3. Screening and Critic al Baseline Assessments  
Screening assessments are  outlined in the Time  and Even ts Table, (Se ction 8.1).  The 
following demogr aphic parameters  will be  captured: year and month of birt h, sex, race 
and ethnicity.  
Medical/medicat ion hist ory will be assessed as related to the inc lusion/exclusion criter ia 
listed in Sectio n 6. 
Written informed consen t must be obtained  prior to per formance of any s tudy related 
procedur es. Screening can take place ov er multipl e days. In particular, the protocol 
requirement  to withhold cholineste rase inhibitors for at least 12 hours prior to the QMG 
and MGC assessments m ay require partici pants to retu rn on a separ ate day  during the 
screening pe riod to ensure they sign an infor med consent form prior to withholding this 
treatmen t.  
 
8.4. Study Assessment s and Procedures 
8.4.1.  Physical Exa ms 
A complete physical examination will include , at a minimum, as sessm ent of t he 
Cardiovasc ular, Respiratory, Ga strointestinal and N eurological sys tems  and skin. Height 
will also be measured and recorded  at screening only and w eight at screen ing and 
baseli ne only.   
A brief physical ex amination will incl ude, at a minimu m, as sessment s of the skin, 
Respiratory , Cardiovascu lar system, and abdomen (liver and spl een). 
 
8.4.2.  Vital Signs  
Vital sign s will be measured i n semi -supine position and  will include temp erature,  
systolic and diastolic blood pressure and pulse rate.  
 8.4.3.  El ectroc ardiog ram (EC G) 
ECGs will be m easured in semi -supine position. 
Twelve-lead ECGs will be obtain ed
  during the study using an ECG machine that 
automatically calculat es the heart rate and measure s PR, QRS, QT, and QTcF interv als.  
Refer to Sect ion 6.8.3 for  QTc F criteria and additi onal Q TcF rea dings that may be 
necessar y. 
 8.4.4.  C linica l Safety Laboratory Assessments  
All pr otocol required laborat ory assessments mus t be conduc ted in accordance with the 
SRM or Laboratory Man ual, and Protocol Tim e and Event s Tables ( Sectio n 8.1 and 
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 45 Section 8.2).   Laboratory requisition form s mus t be completed,  and samples must be 
clearl y labelled with the participa nt number , protocol number, site/cent er numbe r, and 
visit date.    De tails for  the prepara tion and shipment of samp les will be pro vided b y the 
laborator y and are detailed in the S RM or the laboratory manual.  Reference ranges fo r all 
safety parameters will be provided  to the site by the laborato ry res ponsibl e for the 
assess ments . 
If additio nal non- protocol specified la boratory assess ment s are performed  at the 
institution’s local la boratory and result in a change in participant  management or are 
considered cl inically si gnificant by the Investigato r (e.g ., SAE or AE or dose 
modificatio n) the resul ts must  be recorded.    
Hematology, clini cal chemistry, urin alysis and additional parameters  to be tested by 
central laboratory are listed below: 
Hematology  
Platelet C ount  RBC  Indices : Automated WBC Differ ential : 
Red Blood Cell ( RBC)Count  Mean corpus cular 
volum e (MCV) Neutrophil s 
White Blood Cell (WBC) Count (a bsolute)  Mean corpuscular 
hemoglobin  (MCH ) Lymphocytes  
Reticulocyte Count  Mean corpuscular 
hemoglobin  
conc entration 
(MCHC ) Monocytes  
Hemoglobin   Eosin ophils 
Hematocrit   Basophils  
Clinical Chem istry 
Blood urea 
nitroge n (BUN) Potassi um AST (SGOT)  Total  and direct 
bilirubin  
Creatin ine Chloride  ALT (SGPT)  Uric Acid  
Glucose fastin g 
[on Day 1 
(baseline) and 
Week 7 only]  Total carbon dioxide 
(CO 2 ) Gam ma glutamy ltransfer ase 
(GGT ) Albumin  
Sodium  Calcium  (corrected ) Alkalin e phosphatas e (ALP) Total Protein  
Serum 
complement  
(CH50, C3) Immunoglo bulin M 
(IgM) Immun oglob ulin A 
(IgA)  
Immunoglob ulin G 
(IgG)    
Since c hanges in ALP , total protein and alb umin l evel can potentially  unblind the 
invest igator to wh ich dose the partic ipant has been  randomized to ; values for ALP, tot al 
protein, and albu min levels will be blinded to t he site .  An unblind ed Medi cal Monitor 
will review  this lab data o n an ongoing basis for saf ety.   
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 46 NOT E: Details of Liver C hemi stry Stopping Crite ria and Fo llow-Up Proced ures are 
given in Ap pendix 2: Live r Safety Re quired Actions  and Follow up Assessments .  
Routine Urinalysis  
Specific gravity , pH 
glucose, protein, bloo d and keto nes by di pstick  
Microsco pic examin ation (if blood or protein is abn ormal) 
Other tests  
QuantiFERON ®-TB Gold  
Viral Serology [HIV1/HIV2, Hepa titis B (H BsAg), Hepa titis B (Core anti body), Hepatitis C (Hep  C 
antibody]  
FSH (as needed for confirmat ion of pos tmenopaus al status ) 
Preg nanc y Test s:  serum  test at s creening, Week 18, and early wi thdrawal  and urine  dipstick pre -
dose at other timep oints. Positive urine tests should  be confi rmed with a serum te st. 
 
All laboratory tes ts with values that are  considered clinically sig nificantl y abnormal 
during participation in the stud y should be repeated until the values  return to normal or 
basel ine.  If suc h values do not return to normal within a period judged reasonable by the 
Principal  Investigator, the  etiology  should be iden tified , if possib le and the Sponsor 
notified . 
 
8.4.5.  Ph armacok inetics  
Blood samples for PK  analys is of RVT -1401 will be colle cted at the time points  indicated 
in Se ction 8.1 and 8.2, Ti me and  Even ts Tables.  The actual date and time of each  blood 
sample co llection will be recorded.      
Processing, storage and shipping proc edures are provided in th e SRM or lab manua l. 
Serum analysis will be performe d under t he control of t he Sp onsor.  Concentrations of 
RVT -1401 wi ll be determined in serum sam ples using the currently app roved 
bioanaly tical met hodology.  Raw data will be archive d at the bioanalytical site . 
 8.4.6.  Anti-Drug A ntibod y (ADA) and Neut ralizing Anti body ( NAb)  
Blood sample s for ADA and NAb anal ysis will be collected at the time  points i ndicated 
in Se ction 8.1 an d 8.2, T ime and Events Tables .  The actual date and time of  each b lood 
sample collection  will be rec orded.   
Processing, stor age and shipping procedure s are provided in the SRM or lab manual. 
ADA analys is will b e perfor med unde r the control of the Sponsor.  Anti -RVT-1401 
antibody titers will be determ ined in serum s ample s using the curren tly approved 
bioanalytical me thodology.  Raw da ta will be archived at  the bioanalytical site .  If Anti -
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 47 RVT-1401 a ntibody titers  are detected , they will be further characterized usi ng a 
validated cell based N ab assay 
8.4.7.  Phar macodynamics  
Blood samples  for PD an alysis will be collecte d at t imes indicat ed in the Time and 
Events Tables ( Section 8.1  and 8.2).   
Pharmacodynamic Marker s 
Total IgG , and d ifferentiation by class:  
IgG subclasses  (IgG1, 2, 3, and 4)  
 
Anti-AChR an tibody lev els 
The actual  date and time o f each blood sample collecti on will be recorded. T hese samples 
may be used fo r the analys is of exp loratory biomarkers. Sampl es will be colle cted, 
labelled, stored, and shipped a s detailed in  the SR M or la b manual. 
8.4.8.  E xploratory  Bioma rkers  

 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 48 8.5. Myasthenia Gravis Assessment s 
8.5.1.  Myasthenia Gravis Activi ties of D aily Living  (MG-ADL) 
The MG-ADL is an 8 -item, patient reported questionnai re that assesses MG symp toms 
and their effects o n activities of  daily liv ing. The s cale has been  validated and shown to 
correlate with the QMG scale and newer MG outcome scale s such as  the MGC and MG -
QOL15 r [Wolfe , 1999, Muppidi , 2011].  
Participan ts are ask ed to rate each  item on a scale of  0-3.  The MG- ADL score is 
calculat ed by totalling the  rating for each of the 8 items.  The s cale takes ap proxi mate ly 
2-3 min to co mplete and can be admin istered b y the physi cian or trained  clinic p ersonnel 
or study coordinator.  Details  can be found within t he SRM  or study specific manual. 
8.5.2.  Quantitative Myasthen ia Gravis Score (QMG)  
The QMG score was developed as a tool to ass ess MG disease severity and the patte rn of 
deficits bas ed on quantitative testing of affect ed muscle groups [ Barohn, 1998].  The 
scale is comprise d of 13 test items th at are graded on a scale of 0 -3.  The total sum across 
all 13 items rep resents  the QMG Score.  The tes t takes ap proximate ly 30 minutes to 
perform and can be administe red by a trained physician, researc h coordinator or clini cal 
evaluato r who has been trained for this study.   Details can be found within the SRM or 
study sp ecific manual. 
8.5.3.  Myasthenia G ravis Composite  Score (MGC)  
The MGC wa s dev eloped by selectin g the best  performing items from 3 c ommonly use d 
MG-specific scales (QMG, MG manual m uscle test,  and MG- ADL)  and is comprised of 
10 functional domains: 3 ocular, 3 bulbar, 1 r espiratory , 1 neck, and  two limb items 
[Burns, 2008].  The sc ale meas ures symptoms and signs of MG in th ese domains 
incorpor ating both physician and patien t-reported t est items. The MGC takes 
approximately  5 min to comple te and  can be administe red by a trained phy sician, 
research coord inator or c linical evaluator.   Details can be found within the SRM or stud y 
specific manual. 
8.5.4.  Myasthenia Gravis Quality of Life 15 r evised Score (MG -QOL 15 r) 
The M G-QOL15r is  a patient -reporte d scale designed to assess  how their MG aff ects 
different asp ects relat ed to quality of li fe.  Th ere a re 15 items that ar e graded on a scale of 
0-2; the total across all 15 items repre sents the MG -QOL15r score. The surv ey takes  
approximat ely 2 minutes to complete by th e participant .  Details can b e found wit hin the 
SRM or stu dy specific manual. 

 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 49 8.5.5.   Satisfa ction Questio nnaire   
A brief survey asking participan ts for feedback on their expe rience with the SC injections 
durin g the co urse of th e study will be comp leted at the end  of the treatment peri od.  T he 
survey wil l take less  than 2 min to complete  by the p articipant.  
 
9. DATA MAN AGEMENT 
For this study, participa nt data will be entered into a Sp onsor-approved e lectronic 
database and comb ined w ith data provided from other sources (e.g., safety laboratory, PK 
and PD vendor,  etc.) in v alidated datasets then transmit ted electro nically to the Sponsor 
or designee.   
Management of clinical data will be performed in accordance wi th app licable  Sponsor 
approved standards an d data cleaning p rocedures to ensure t he int egrity of the data, e .g., 
removing errors and inconsisten cies in the da ta. 
Adverse events and concomitant medi cations terms will be coded using Medical 
Diction ary for Re gulato ry Acti vities (Me dDRA) a nd the World H ealth Organizat ion 
Drug Dictionary En hanced  (WHO-DDE ), respectively.   
The Principal Investigator  will retain or iginal s ource documents and the Sponsor w ill 
receive e CRF -required data as  electronic datasets. Part icipant initials will n ot be collected 
or transmitted to th e Sponsor. 
 
10. STATISTICA L CONS IDERATIONS AND  DAT A 
ANALYSES 
10.1.  Sample Size Considerations 
The sample s ize for t his study was not determined using statistical me thods.  The sampl e 
size was chosen based on c linical and  recruitment  considerations.  However, the sampl e 
size of 14 active and 7 pla cebo pa rticip ants will allow the study to show a 3 3% di fference 
between either active arm and the placebo  arm, assuming 90% power, equal standard 
devia tions of 20 an d an alpha of 0.05 us ing a two -sided z-t est for the primary  endpoint of 
percentage chang e from ba seline i n IgG at Week 7.  
10.2.  Data An alysis Co nsiderations 
10.2.1.  Anal ysis Populations  
Intention -To-Treat (ITT) Population 
All e nrolled par ticipants who ta ke at least one dose of st udy me dication will be inclu ded 
in the ITT popula tion.  Participant s will be sum marized by randomized treatment group. 
This will be the population f or all PD  parameters.  
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 50 Safety Population  
All participant s who enrol l in the study a nd receive at least one dose of stu dy treatme nt 
will b e included in the Saf ety Population.  Participant s will be sum marized by  actual 
treatment g roup. 
This will be the popula tion for the safety analyses, as well as for presentati on and 
summarization of bas eline/demogr aphic characte ristic s. 
Pharmacoki netic Pop ulation 
The PK Popula tion will include all partic ipant s who undergo plas ma PK sampling and 
have eval uable concentrati on-time data for analysis.  
Pharmacodyn amic Population  
The PD populat ion will include al l participan ts who have basel ine me asure, along with a 
post baseline mea sure and receive at least one d ose of study treatment. 
Open -Label Extensi on Population  
The OLE population will include all participants who enroll in the OLE and receive at 
least one dose of study treatment in the OLE.  
12-Week Follow up Population 
The 12-Week Follow up Population wi ll include all participants who receive at le ast one 
dose of study treatment in Part 1 and decline participation in the OLE but continue with 
the 12-week follow up period.  
 
10.2.2.  Interim Analysi s 
An interim ana lysis will occur after the last subject completes t he Week 7 visit  of the 
study.  All endpoints wi ll be evaluat ed for thi s analysi s.  A fina l analysi s will occur when 
the last subject completes  or discontinu es the study.  Since this analysi s is occu rring a t 
the en d of the double-blind treatment phase, no a djustments  of the alpha level are 
necessa ry.  T his analys is will s erve as  the prima ry analys is and a s econd ana lysis will 
occur, summa rizing the endpoints after th e trea tmen t-free phase.  
10.3.  Final Analysis  
Final an alysis will be performed after the comp letion  of the study and the database is 
locked.  
Data will be liste d and sum marized.  Treatment will be assigned based  on the dosing 
schedule and included in the data lis tings.  Listings will b e sorted by participant , day, an d 
time; summa ries will be presented by  treatment , day, and time.  
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 51 Unless sta ted other wise, descrip tive s umm aries for cont inuous va riables wi ll includ e n, 
mean, standard dev iation (SD), median, first an d third quar tiles, minim um, and 
maximum.  T he ge ometric  mean  with associated 95% confidence interval ( CI), and the 
between -particip ant CV (% CVb) for P K paramet ers only will als o be included.  For 
categorical variables, n a nd pe rcent will be used as  summary  statistic s. Baseline i s the last 
available asses sment prior to  time  of the first dose unless it is spe cified otherwise.  I f 
there are  multiple assessments collected on the sam e schedul ed time, the average of these 
assessm ents will be used.  For tabulated sa fety sum maries, only t he scheduled 
assessments  will b e included in  the summary tables . 
Vers ion 9.4 or higher of the SAS s ystem will be u sed to analy ze the da ta as well as to 
generate tables, fi gures, and listings.  
Comple te details will be documen ted in the Statistic al Analysis  Plan (SAP) , which will 
be signed off prior to the lock of the s tudy d atabase.  
 
10.3.1.  Primary End point for Ef ficacy 
The primary endpoint will be defined as the percentage change fr om Baseline in the IgG 
parameter at  Week 7.  The endpoint w ill be summari zed using a 6-number su mmary 
including the s ample si ze, mean, st andard d eviation, median, m inimum an d maximum 
values.  T reatment group comparisons between t he two active (separately) to the placebo 
arm wil l be perf orme d using an Analysis  of Covari ance model with treatment a nd 
baseline value in the m odel.  An alpha of  0.05 will be us ed to determine s tatistical 
signif icance. 
10.3.2.  Seco ndary Endpoints for Efficacy  
The secondary endpoint s for effic acy are Immunogenic ity de termine d by percentage 
change f rom B aseline i n anti -RVT -1401 antibodies and  characterizat ion of a ny anti-
RVT-1401 ant ibodie s to confirm neut ralization potent ial at W eek 7.   
For each of the continuous secon dary endpoints, the actual value, change fro m baseline 
and percenta ge change fro m baseline fo r all secondary endp oints will be summarized b y 
visit and treatment  group using the n, mean, SD, median, firs t and  third quart iles, 
minimum, and maximum  valu es.  The compari son of the active arms (separately ) to t he 
placebo arm  will be performed using an Analysis of Covarianc e mod el with treatment 
and basel ine value in  the model.  An alpha of 0.05 will be used to determi ne statistical 
significance.  If deemed appropriate, the tw o active arms ma y be combine d and com pared 
to placebo to evaluate an y treatment effect.  
For categori cal secondary en dpoints, t he numbe r of par ticipants wh o me et the endpoint 
and the percentage w ill be summa rized.  The percentage will be c alculated using those 
participants  who  had a value at t he time point.  Statistical te sting may b e performed 
between the two  treatments  using a F ishers Exact Tes t.  If deemed appr opriate, the two 
active arms may b e combined and compared to placebo to evalua te any  treatment ef fect. 
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 52 10.3.3.  Safety  Analyses 
Safety w ill be  evaluated by assessment of cl inical  laboratory tests, physical  exam inations, 
vital signs  measure ments, and ECG readi ngs at various time  points during t he study, and 
by th e documentation of AEs.  
AE verbatim text will be  coded and clas sified by body system  and p referred (coded) term 
using th e Med DRA.  All AEs, both serious and non- serious will be listed .  AE summa ries 
by study part and tre atme nt group, of the number and percent of participant s reportin g 
each event at leas t once will be gene rated.  
Clinical che mistry, hematology, and urina lysis valu es will be listed for each participant  
and flagg ed high or low r elative to the nor mal range where appropriate.  Descrip tive 
summ ary statistics will be created b y study part, treatment and assessment  time.  
Othe r safety  data will be s ummarized des criptively by treatment and time.  Details will be  
provided in t he SAP. 
10.3.4.  Phar macok inetic Analyses 
Serum  comp ound c oncentrati on-time data will be analyzed by non -compartmenta l 
methods with Phoenix WinNonlin or other PK soft ware p rograms.  Calculations will be  
based  on the actual sampling times recorded duri ng the stu dy.  From the pl asma 
concent ration-time data, the f ollowing pri mary PK parameter s will be determined  (if 
possibl e):  
AUC(0 -t), Cmax , tmax, Ctrough   
Additional P K pa rameters  may be calculated .  PK data will be pr esented in graphical and 
tabular form and will b e summariz ed descr iptive ly.   
10.3.5.  Pharmacodynamic A nalyses 
All participant s in the ITT po pulation will be included in t he summaries of PD data.  The 
actua l value, ch ange fro m ba seline and percentage change f rom baseline for all PD 
paramete rs wil l be summ arized by visi t and tr eatment grou p using the n, mean, SD, 
medi
an, first and third quartile s, minimum, and maximum values.  Statistical test ing may 
be performed between the tw o treatment gro ups using mixed mode ls.  Details will be 
provided in the Statistic al Analysi s Plan.   
Serum IgG, IgG subclass (1 -4), and an ti-AChR leve ls will be summarized as both raw 
values as well  as percent change f rom baseline (i ntra-participan t assessment ). Additional 
PK/PD and PD/PD r elationships may be evaluated.   PD data wi ll be presented in 
graphic al and tabul ar form and will be  summa rized descriptively.    
The comparison of the active arms ( separately) to the placebo arm will be performed 
using an Anal ysis of Cov ariance model with t reatment and baseline value in the mo del.  
An alpha of 0.05 wi ll be used to determine statistical s ignificance.  
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 53 10.3.6.  Other Analyses  
 
10.3.1.  OLE and Follow up Analyses 
Data listings and summaries will be provided separ ately for the OLE and 12- Week 
Follow up Populations. Descriptive Analyses will be presented by randomized treatment 
assignment from the double-blind t reatment period and overall.  Baseline will be 
specified  in the Statistical Analysis Plan.  If there are multiple assessments  collected on 
the same scheduled time, the average of these assessments wil l be used.  Only the 
scheduled assessments will be inclu ded in the summary tables.  All OLE and follow up 
analys es will be based on the OLE and 12-Week Follow up Populations, respectively.  
Ad hoc statistical analyses such as two sample t -test or Chi-Squar e test, may  be 
performed for the changes or shifts at we eks 8, 10, and 12 separately.  The significance 
will be evaluated at a 0.05 two-sided level for informational purposes only.  
 
11. ADVERSE EVENTS (AE) AND  SERIOUS ADVERSE 
EVENTS (S AES) 
The Pri ncipal Investi gator or site staff is res ponsible for det ecting, documenting and 
reporting event s that meet the definition of an AE or SAE.   All SAEs m ust be reported to 
the Sponsor within 24 hours of aw areness of the event (S ection 11.2).  
Once former study part icipants have completed t he study , the Principal Investigator  is not 
oblig ated to actively seek AEs or S AEs. However , if the Principal Investigator learns of 
any SAE, i ncluding a death, at any time after a partici pant has been discharged from the 
study, and he/s he considers the event reas onably related to the invest igational  product or 
study participatio n, the Principal  Investigator must promptly notify the Sponsor. 
 

 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 54 11.1.  Definition of Adverse Events 
An AE is a ny unt oward medical occurrence i n a participant  or clinical investigation 
participant, temporally associated with  the use of a  medicinal product, whethe r or not 
considered related to the medicinal product. 
An AE can therefore be any unfavorable and unintended sign (i ncluding an abnormal 
laboratory finding), sympt om, or disease (new or exacerbated) temporally associated  with 
the use of a medicinal pr oduct. 
Events meeting the definition of an AE include  but are not limited to : 
• Any clinically significant, new or wor sened , abnor mal laboratory tes t results 
(hemat ology,  clinical chemistry , or urina lysis) or other safety asses sments (e.g ., 
ECGs, radiologica l scan s, vital signs measurements) . Clinical significance is 
determined based on t he medical and scientific judgemen t of the Inv estigator.  
• Exacerbation of a chroni c or intermittent pre -existing c ondition including an 
increase  in fre quen cy and/or intensity of the con dition.  
• Signs, symptoms, or the clinical sequelae of a suspected interaction  (e.g. with 
medications or food). 
• Signs, symptoms, or the clinical sequelae of a o verdose of eithe r investiga tional 
product or a concomit ant medicatio n (overdose without an AE should be report ed 
as a protocol deviation).  
Events that do not  meet  the def inition of an AE include: 
• Anticipa ted day-to-day fluctuations of pre -existing co nditio n(s), including the 
disease under study, that do not repr esent a cli nically significant exacerbati on or 
worsen ing. 
• Abnormal or worsening laboratory, imaging, or other saf ety findings that are not 
clinical ly significa nt. 
• Medical or  surgical procedures (e.g. , endoscopy, append ectomy);  the condition 
that leads to  the procedure is an AE.  
• Situatio ns whe re an untoward m edical occurrence did not occur (social and/or  
conve nience admission to a hospital). 
 
11.2.  Definition an d Reporting of Serious Adverse Events  
Serious a dverse events mu st be marked as a SAE within the AE eCR F form, w hich will 
send an immedi ate au to notification  to and 
the Medica l Monito r.  
If the eCRF  is not available, the s ite must ema il 
and the Medic al Monitor wi thin 24 hours 
of the study  site personn el’s knowledge of the even t.  
A SAE is any  untoward medical occurrence that, at any dose:  

 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 55 • Resu lts in d eath 
• Is life -threatening  
The term 'life-threat ening' in the defi nition of 'serious' re fers to an event  in which the 
participant  was at risk o f death at th e time of the event.   It does not refer to  an event, 
which hypothetically might have caused death, if it were more severe.  
• Requires hospitalization or prolongation of existing hospita lization 
Hospitalization planned prior to signing the inform ed consent is  not considered an S AE.  
Surgeries and other interventions that were under consideration prior to signing the 
informed consent are not cons idered an  SAE if the underl ying condition has not changed 
from ba seline.  
“Hospitalization” includes admissio n to the hospital of any duration.  It does not include 
emergency room visits . Complications that occur during hospitalization are AEs  and are 
SAEs if they prolong hospital ization or fulfill a ny ot her serious crit eria. 
Hospi talization for elective treatmen t of a pre-existing condition  that did not worsen f rom 
baseline is not considered an AE. 
• Results in disability/incapacity  
The term disability mea ns a substantial disruptio n of a person’s abil ity to conduct normal 
life functi ons.  This definition is not i ntended  to include experiences of rel atively minor 
medical significance such as uncomplicated headache, nausea, v omiting, dia rrhea, 
influenza, and accid ental t rauma (e.g. sp rained ankle) which m ay in terfere or prevent 
everyday  life functions but do not const itute a substantial disruptio n. 
• Is a congenital ano maly/birth defect  
• Is an important medical event that may jeo pardize the subject or may require me dical 
or surgical inter vention to prevent one of the other outcom es listed in the above 
definition. Exampl es of such e vents are allergic bronchospasm, blood dy scrasias or 
convulsions where treatment prevents the need for hospitaliz ation. 
The following should  alway s be considered ser ious:  invasive or malignant cancers,  and 
developme nt of drug dependency or d rug abuse. 
  
11.3.  Time Period and Frequency for Collecting AE and SAE 
Information 
• AEs will be collected from the time of  informed consent until the follow -up c ontact,  
at the timepo ints specified in th e Sect ion 8.1 and 8.2, Time and Eve nts Tab les. 
• Medical occurrences that begin prior to any study procedure but after obtaining 
informed consent may be recorded on t he M edical History/Cu rrent Medical 
Conditions s ection  of the e CRF.  
• All SAEs will be r ecorded and reported to the Sponso r within 24 hours of site 
awareness.  
• Any SAEs assessed as related to s tudy pa rticipation ( e.g., protocol -mandat ed 
procedures , invasive te sts, or change in exi sting therapy) o r related to inves tigational 
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 56 product will be recorded from the tim e a partici pant consents to participate in the 
study up to and including any follow-up contact.  
• Once form er study pa rticipants  have completed the study,  the Principal Invest igator 
is not obligated to  activel y seek AEs or SAEs. However, i f the Principal Investigator 
learn s of any SA E, including a death, at a ny time after a  participant has been 
discharged from the study, and he/she co nsiders th e event reaso nably related to the 
inves tigational produ ct or study participation, the Principal In vestigator must 
promptly noti fy the Sponsor. 
 
11.4.  Method of Detecting and Reporting AEs an d SAEs  
Care will b e taken  not to introduce bias when detect ing A Es and/or SAEs.  Open -ended 
and non- leadin g ver bal qu estio ning of th e part icipant  is the preferred method to inquire 
about A E occurrence.  Appropriate questions include: 
• “How ar e you feeling?”  
• “Have you had an y (othe r) medical pr oblems sinc e your las t visit/conta ct?”  
• “Have y ou taken any new medi cines, othe r than those provided in this study, since 
your last visit/contact? 
All AEs and SA Es sh ould be promptly recorded in the eCRF , completing all fields for 
which  data is available.  When known, the diagnos is should be entered as  the event term 
in the eCR F, rather than individual s ymptoms.  When the diagnosis is unclear, key 
sympt oms may be ent ered, and the investigator should obtain appropriate t ests to 
establish a diagn osis, if poss ible.  Disc harge summaries  should be requested for all 
hospitalizations. 
For SA Es, the eC RF will sen d an auto notification  to 
and the Medical Monitor when the form is 
saved.  Each SAE should be assigne d a cau sality at the  time of entry, as th is is require d to 
determin e regulatory reportin g. Follow-up inf ormat ion regardi ng the SAE, including 
hospital discharge summary, should be e mailed to 
 
11.5.  Assessing Severity of AEs and SAEs  
Severity describes the i ntensity of a  specific event (as in mild , moderate, or severe 
myocar dial infarcti on); the  event itself, however, may be of relatively minor  medical 
significance, such  as a severe headache.   This is not the s ame as “serious,” which i s based 
on participant /event outcome or action taken.  
The I nvestigator must dete rmine  th e severi ty of each  AE acco rding to the following 
criteria:   

 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 57 Criteria for Deter mining the  Grade/Severi ty of Adverse Event Terms   
Grade  Criteri a  
1/Mild   Asymptomat ic or mild symptoms,  clinic al or diag nostic 
observatio ns only; intervention not indi cated  
2/Modera te  Minimal, loc al, or noninvasive intervention indicated; 
limiting ag e-appro priate instrumen tal activities of daily 
living  
3/Severe  or medically 
signific ant  Not immediately  life-threatening ; hospitalization  or 
prolo ngation of hospitaliza tion indic ated;  disabli ng; limiti ng 
self-care activities of dai ly living   
4/Life -threatenin g  Life threaten ing consequences; urgent i ntervention 
indicated   
5/Death   Deat h related to adverse  event   
  
Advers e eve nt severity should be recorded in the appropria te section of th e AE eCRF  and 
in the participant ’s source documents. 
 
11.6.  Assessing Causal ity of AEs and SAEs 
Regulatory authorities r equire that both investigator and sponsor assess whether there is  a 
reaso nable possibility that the stud y treatment caused each AE.  This  assess ment requ ires 
careful medical considerati on of each  event  in relatio nship t o the timin g of drug 
administration, the presence of other factors which may ha ve caused the event 
(underlying  illness, concomitant m edicatio n, complications, exposure t o other to xins or 
allergens, environmental factors, e tc.), and the effects of st opping and/or rest arting the 
study treatment.  The following definitions are to be use d for the relationship of the AE  
to Study Treatment:  
The inve stigator will ass ess the cau sality of each report ed AE as follows:  
 
• Probably rela ted: an AE occurring at  a reasonab le time following administration of a  
drug, where other causes are unlikely , there is evidence to s uggest that  the d rug 
caused the event,  and/or where the event re curs after reint roduction of the drug 
(without other explanation for the recurrence).  
• Possibly related: an AE  occurring at  a reaso nable time  follo wing  administration of a 
drug and for which there is a reasonab le possibility th at the drug caused the ev ent, 
e.g. t here is so me evidence to suggest a causal relationship.  
• Not related: an AE  with  poor or no relati onship to the timing of dr ug administratio n, 
or where another cause such as underlying dise ase, com plications, or other 
medication s reasonably expl ains the ev ent, or where  the event does not recur after 
continue d administration or reintro ducti on of the dru g for an adequate period. 
 
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 58 11.7.  Follow-up of AEs and SAEs 
After the initia l AE/SAE report, the Pr incipal Investigator  is required to pr oactively 
follow e ach event  at su bsequent  visits/contacts  until the event resolves.  All SAEs and 
AEs will be  followed until r esolution, or until the co ndition stabilizes or until the 
particip ant is lost to follow -up. Where neces sary, repeated laborato ry testing should be 
reque sted t o con firm res olution. Ongoing AEs where no further information is likely to 
be av ailable may be cl osed after consultation be tween the Sponsor and Medical Monitor. 
11.8.  Regu latory Reporting Requirements for SA Es 
Prompt notificatio n by the Investigator  to the Sponsor of SA Es/adverse event of special 
interest ( AESIs ) is essential so that  legal  obligations and e thical responsibilities towar ds 
the safety  of subjects and the sa fety of a product under cl inical inve stigation are met.  
 
The Sponsor has a legal r esponsibil ity to not ify both th e local regulatory authority and 
other regulatory agencies about t he safety o f a product under clinical investigation. The 
Sponsor will comply with country specific r egulatory r equirements relating to  safety 
reporting to the regu latory  authority , IRB/IEC a nd Investigator. 
 Investigator s afety reports are prepared f or suspected unex pected serious adverse  
reactio ns (SUSARs) a ccording to local regul atory requirements and are forward ed to  the 
Investigators in  accordance with local reg ulatio ns. 
 The I nvestigator  who receives an Investigator safety report describing a SAE( s)/AESI(s)  
or other specific safety inform ation (e.g., summ ary or listing of SAEs)  from the Sponsor 
will fil e it with the IB and will notif y the IRB/IEC, as appropr iate accor ding to lo cal 
require ments. 
 
11.9.  Overdose  
Overdose is less likely in a study where the  drug is adminis tered within a clinical unit b y  
a healthcar e provider.  If there are  no symptoms of an overd ose, it ma y be recorded as a 
protocol deviation.  Overdose with sympto ms sh ould be recor ded as an AE or SAE, as 
appropriate.  
 
12. PREGNANCY REPORTING 
All female partic ipant s will be tested for preg nancy prior to study drug dosing. 
Participant s testing positive for pr egnancy will be ineligible  for study participation.  
Any p regna ncies  in a subje ct, or the partner of a subject, between the time of informed  
consent and stud y termination must be rep orted to the Sponsor within 24 hours of 
learning of the pregnanc y. Informa tion on the status and health of the mother, the 
pregnancy and its o utcome, and  the child will be recorded on the form provided. In case 
of a par tner pregnancy, the partner of the st udy subject will b e asked to sign a partner 
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 59 pregnancy consent fo rm in order to collect pregnancy and out come information.  
Informatio n on the stat us of th e mother and child will be forwarded to the Sponsor.  
General ly, follow-up will be no longer than 6 to 8 we eks following the estimated delivery  
date.  Any premature te rmination of the pregnancy will b e repor ted. 
 
13. RESPONSIBILI TIES  
13.1.  Principal Inves tigat or Respo nsibilities  
13.1.1.  Good Clinical Prac tice (GCP) 
The Principal Inve stigator will en sure that this study is co nduc ted in accordance with the 
principle s of the “Declaration of  Helsinki”  (as amended in Edinburgh, Tok yo, Venice, 
Hong K ong, and South Afric a), International Conference on Harmonisation (ICH) 
guidelines, or with the l aws and regulations of the country in which the research is 
conducted, whiche ver affords the greater pro tection  to the study participa nt.  Fo r studies 
conducted under a Unite d Sta tes IND, th e Principal Investigator  will en sure that the basic 
principle s of “Good Clinic al Practice,” as outlined  in 21 Code of Fed eral Regulations 
(CFR 312), subpart D, “Responsib ilities  of Sponsors and Investi gators,” 21 CFR, part 50, 
1998, and 21 CFR, par t 56, 1998, are adhered to.  These stand ards are consistent with the 
requirements of the European Community Dir ective 2001/20/EC. 
Since this is a “covered ” clinical trial, the  Principal Investigator  will ens ure that  21 CFR, 
Part 54, 1998, is a dhere d to; a “covered” clinical trial is any “study o f a drug or device in 
humans submitted  in a m arketing application or re classification petition participant  to this 
part that the applic ant or FDA  relies on to establish th at the product is effe ctive 
(including stu dies that s how equivalence to an effective product) or that make a 
signi ficant contribut ion to the demonstration of sa fety.”  This r equires that Principal  
Investigator s and all s ub-investig ators must  provide docume ntation of their financial  
interest or arrangements w ith the Sponsor, or proprietary interests in the drug being 
studie d.  This documentation must be provided b efore  particip ation of the Principal  
Investigator  and any su b-investiga tor.  The Principal In vestigator and sub- inves tigator 
agree to  notify the Sponso r of any change reportable int erests during the study and f or 
one year foll owing completion of the st udy. Study completion is defined as the dat e that 
the last participant  has completed the protocol de fined activities.  
13.1.2.  Institut ional Revie w Boa rd (IRB)/In dependent Ethics Committee 
(IEC) Approval  
This protocol and a ny accompanying m aterial to be p rovided to the participant ( such as 
informed consent f orm, advertisements,  participa nt information sheets, or descriptions of 
the study used to obt ain inform ed con sent) will be submitted by the P rincipal Investigator  
to an I RB or IEC.  Approval from the IRB or IEC m ust be obtained be fore starting the 
study and should be document ed in a le tter to the Principal I nvestigator specifying the 
protocol number, p rotocol ver sion, protocol date, documents reviewed, and date on which 
the com mittee met and granted the approval. 
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 60 Any modifications made to the protocol a fter receipt of I RB or I EC approval mus t also be 
submitte d to the IRB or IEC for approval before imple mentation. 
The investigator will be responsible for the following: 
• Providing written summ aries of the status of th e study to the IRB/IEC on an 
annual basi s or more frequently in accordance with the requirements,  policies, and 
procedures est ablish ed by  the IRB/IEC. 
• Notifying the IRB/IEC of SAEs or o ther significant safety findi ngs as required b y 
procedures established by t he IRB/IEC.  
 
13.1.3.  Informed Consent  
The Pr incipal Investigator  or designee is r esponsible for obtainin g written inform ed 
consent  from each individual  partici pating in this study after ade quate explanation of the 
aims , methods, objectives, and potential hazar ds of the study an d before undertaking a ny 
study- related procedures . The  Principal Investigator  must  utilize an IRB or IE C-approved 
conse nt form fo r documenting written  informed consent . Each informed consent will be 
appropriately signed and dated by the participant  and the person obtaining cons ent.  
Participants must be re -cons ented  to continue their pa rticipation in the study i f a pr otocol 
amendm ent is made th at substantially alters th e study design or the potenti al risks or 
burden to the parti cipant.  
 13.1.4.  Confidentia lity 
The Pr incipal Investigator  must assure that participants’ an onymity will be strictly 
maintained and that th eir identit ies are pr otected fro m unauthorized parties.  Only 
participant number (i.e., not names)  and month and year of bir th (as allo wed)  should be 
recorded on any form or bio logical  sample submitted to the Sponsor, IRB or IEC, or 
laboratory. The Princip al Investig ator must keep a screen ing log showing codes, names, 
and addresses for all participan ts screened and for all  participants en rolled in  the trial.  
The Principal Inves tigator must keep a screening log showi ng codes, names, and 
addresses for all part icipants screened an d for all  participants enrolled in the tria l. 
The Principal Investigator  agrees th
 at all  information re ceived from  the Sponsor, 
including but not limited to  the IB, this protocol, e CRFs, t he in vestigational new dru g, 
and any other study inf ormation, r emain  the sole a nd exclusive property of the Sponsor 
during the conduct of the s tudy and there after. This i nformation is not to be disclo sed to 
any third party  (except employees or agents direc tly involved in the conduct of the study 
or as  requi red by  law)  with out prior wri tten consent from the Sponsor. The Principal 
Investigator f urther agrees to  take all reas onable precautio ns to pr event th e disclosure by 
any employee or agent  of the study sit e to any third party or ot herw ise into the publi c 
domain.  
 
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 61 13.1.5.  Stud y Files an d Rete ntion of Records  
The Principal I nvestigator  must maintain ade quate and accurat e recor ds to e nable the 
conduct of  the stud y to be fully document ed and the study data to be subsequen tly 
verified.  These documents should be clas sified int o at least  the follow ing two categories: 
(1) Investig ator’s study file, and (2) pa rticipant clinic al source docu ments. 
The Inves tigator’s stud y file will contain th e IB, protocol/amendments, e CRF an d que ry 
forms, IRB or IEC and governmental approval with c orres ponde nce, inform ed consent, 
drug records, staff curriculum vitae and authoriz ation and training forms, and other 
appropriate documents and correspondence. 
The re quired source data should include t he following for each participant : 
• participa nt identificatio n (na me, month and year of birth, gender); 
• docum entation that participant meets el igibility c riteria, i.e.,  history, ph ysical 
exami nation, and confirmation of diagnosis (to support inclusion and e xclusion 
criteria);  
• participation in trial ( including t rial numbe r); 
• trial dis cussed and date of informed consent; 
• dates of all visits; 
• docu mentation that protocol spec ific procedures  were pe rforme d; 
• results of efficacy  parameters, as required by the pr otoco l; 
• start and end date (in cluding dose regim en) of tri al me dicat ion (prefer ably drug 
dispensing and return should be documented as well); 
• record of all A Es and other s afety parameter s (start and end date, and preferably 
including causality and intensit y); 
• concomitant medication  (including start and end date, dose if re levan t; dos e 
chan ges should be motivated); 
• date of trial completion and reaso n for early  discontinuation, if appli cable.  
All clinical study documents must be retained by the Principal Inve stigator until at least 2 
years after the last approval of a marketi ng applicatio n in an ICH region (i.e., Unit ed 
States, Europe, or Japan) and  until there are no pending or contempl ated mark eting 
applications in an ICH re gion; or, if no application is fil ed or if the application is not 
approved for such indicati on, until 2 y ears aft er the investigation is discontinued and 
regulatory authoriti es ha ve been  notified.  The Pr incipal Inve stigator may  be required to 
retain docum ents longer if required by applicable r egulatory requirement s, by local 
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 62 regulatio ns, or by a n agr eemen t with the Sp onsor.  The  Principal Investig ator must notify 
the Sponsor bef ore destroyin g any clinical  study recor ds. 
Should t he Pri ncipal Investigator  wish to assign the study records to another party or 
move them to another location, the Sponsor mus t be not ified in  advance.  
If the Principal Inves tigator  cannot guarantee this arch iving requir ement at the s tudy site 
for any or  all of t he documents, special ar rangements must be made between the P rincipal 
Investigator and  the Sponsor to st ore these in se aled con tainers outside of the site so that 
they can be returned sealed to the P rincipal Inve stigator  in cas e of a regulato ry au dit.  
When source documents are required for the continued care of t he participant, 
appropr iate copies should be made for storag e out side of the s ite. 
Biological samples at the  conclusion of this study may be  retained in storage by the 
Sponsor for a p eriod  up to 10 y ears for purposes of this study.  
 
13.1.6.  Electronic Case Repo rt Forms (eCRF)  
For each parti cipant  enrolled, a n eCRF mus t be compl eted and si gned by the P rincipal 
Investigat or or sub- investigator (as ap propriate) within a reasonable time period  after data  
collection.  This also appli es to records for those participan ts who fail to complete th e 
study (even  during the s creeni ng pe riod if an  eCRF wa s initiated).  If a participan t 
withdraws  from the study, t he re ason must b e noted on the e CRF .  If a participant is 
withdrawn from the study because of a treatment -limiting AE, th orough efforts should be 
made to  clearly d ocument the  outcome. 
 13.1.7.  Drug Accou ntability  
The Principal Investig ator or designee (i.e., pharm acist) is responsible for ensuri ng 
adequat e accountability o f all used and unused investigational product including pla cebo.  
This includes acknow ledgment of recei pt of each shipm ent of study pro duct (quantity and 
condition), participant  dispensing records , and retur ned o r destroyed stud y product.  
Dispensing recor ds wi ll document quant ities received from the Sponsor an d qua ntities  
dispensed to participant s, including lo t number, d ate disp ensed, par ticipant identifier 
number, and the initials of the person dispe nsing t he m edication. 
At st udy initia tion, t
 he monitor will e valuate the site ’s standard operating procedure for 
investigational medicina l product disposal/des truction in order to  ensure that it complies 
with the Sponsor requirements.  Drug may be ret urned or des troyed on an ongoing ba sis 
during the study as  appr opriate.  At the en d of the study, following final dr ug in ventory 
reconciliatio n by the monitor, the stud y site  will dispose of and/or destroy all unused 
investigational medicinal product suppl ies, including empty containe rs, according to 
these procedur es.  If the  site canno t meet the Sponsor’s requirements for disposal, 
arrangements  will be made between  the site a nd th e Spo nsor or its  representative for 
destruction or return of unused investigatio nal medicinal  product supplie s. 
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 63 All d rug supplies and associated documentation will be period ically reviewed and 
verified by the study moni tor over the course of the study. 
 
13.1.8.  Inspect ions 
The Pr incipal Investigator  should understand that source document s for this trial s hould 
be made available to  appropriately qua lified personnel from the Sponsor or its 
representatives , to IRBs or IECs, or to r egulatory authority or health au thori ty inspectors. 
 13.1.9.  Protocol Compliance  
The Principa l Investigator  is responsible for ensuring th e study is co nducted in 
accordance with the procedures and evaluat ions described in this protocol. 
 
13.2.  Sponsor Responsibilities  
13.2.1.  P rotocol Modifications  
Protocol modifi catio ns, except th ose intended to reduce im mediate risk to study 
participant s, may be made on ly by the Sponsor. 
13.2.2.  Study  Repor t and Publicat ions 
A clinical study report will be prepared and provid ed to the regulatory agenc y(ies).  T he 
Sponsor w ill ensure that  the rep ort meets the standards set out in the ICH Guideline for 
Structure an d Conten t of Cli nical Study R eports (ICH  E3).  Note that an ab breviated  
report may  be prepared in certain cases.  
 13.2.3.  Posting of Information on Public ly Available Clin ical Trial 
Regis ters 
Study information from this protocol will b e posted on publicly availabl e clinical trial 
registers before enroll ment of participant s begin s.  Results will be posted as required. 
 
13.3.  Joint Inv estigator/Sponsor Responsibilities 
13.3.1.  Access to In forma tion f or Mo nitoring  
In acco rdance with ICH Good Clinical Pr actice guidelines, the study monit or must hav e 
direct access  to the Pri ncipal Investigat or’s source documentati on in order to verify the 
data record ed in the eCRF s for con sistency.  
The monitor is r espons ible for rout ine review  of the e CRFs at regular inter vals 
throughout the study to ver ify adhe rence to the protocol and the compl eteness, 
consistenc y, and accuracy o f the data being entered on them.  Th e monitor should have 
access to any particip ant records  needed to  verify the  entries on the e CRFs.  The Prin cipal 
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 64 Investigator agrees to coo perate w ith the monitor to ensure that a ny problems dete cted i n 
the course of t hese monitoring visits are  resolved. 
 
13.3.2.  A ccess to Information for Auditing or Inspe ctions 
Representati ves of regula tory authorities or of the Spons or may conduct inspections or 
audits of t he cl inical study.  If the Pri ncipal Investigat or is notified of an in spection by a 
regulatory authority th e Principal Investigato r agrees to notify th e Sponsor m edical 
monito r immediat ely.  The Principal Investigat or agrees to provide to repre sentatives of a 
regulatory agenc y or the S ponsor access to record s, facilities, an d personnel for the 
effective conduct  of any  inspection or audit. 
 13.3.3.  Study Disconti nuation 
The Sponsor r eserves the r ight to terminate the study at  any time. Should this be 
necess ary, the Sponsor will arrang e discontinuati on procedures and notify the  appropr iate 
regulatory authority (ies), I RBs, and IECs.  In termina ting the study, the S ponsor and the 
Principal  Investi gator will assure that adequate consideration is given to the prot ection  of 
the participant s’ interests . 
 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 65  
14. REFERENCES  
Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bry an W.  Reliability testing of 
the quantitative my asthenia gravis  score. Ann NY Acad Sci 1998; 841:769-72. 
Burns TM, Conaway MR, Cutter GR, Sande rs DB; M uscle Study Group. Construction of 
an efficient evaluat ive instrument f or myasthenia gravis: the MG composit e. Muscle 
Nerve. 2008 D ec;38(6):1553-62. 
Evoli A, Iorio  R. C haracter istics o f myasthenia gravis with antibodies to muscle -specific 
kinase an d low- density  lipoprotein- related recep tor protein 4. Cl inical  and Experimental  
Neuroimmunology. 2015;6:40-48. 
FDA Gui dance for Industry  Drug-Induced Liver Injur y: Premark eting  Clinical 
Evalua tion, 2009. 
Furst, DE. Serum Immunoglobulins and Risk of Infe ction: How Low C an You Go?  2008 
Elsevier I nc. Semin Arthritis Rheum 39:18-29 
Gilhu s NE, Vershuuren JJ. Myasthenia gr avis: subgroup classificat ion and therapeutic 
strategies. Lancet N eurol. 2015 O ct;14(10):1023-36. 
Hendrikx J, H aanen J, Voest E, Schellens J , Hui tema A , Bei jnen J.  Fixed Dosing of 
Monoclonal Antibodies in  Oncology. The Oncologist 2017; 22:1212-1221 
Higuch i O, Hamuro J, Motomura M, Yam anashi Y. Autoantibodi es to low-dens ity 
lipoprote in receptor -related protein 4 in myasthenia gravis. Ann Neurol. 2011 
Feb;69(2):418-22. 
Howar d JF, Argenx. A double-blind placebo-controlled study to evaluate the safety and 
efficacy of FcRn -antagonist ef gartigimod (ARGX -113) in generalized mya sthenia gravi s. 
American Academy of Neurology  (AAN) Annual Meeting, 24 Apr 2018, Los Angeles, 
CA. 
Liu JF, Wang WX, Xue J, Zhao C-B, You H-Z , Lu J -H, Gu Y. C ompar ing the 
Autoantibody Leve ls and Clinical E fficacy of Doubl e Filtration Pla smapheresis, 
Immunoadsorption, a nd Intravenous Immunoglobulin for the Treatme nt of Late -onse t 
Myastheni a Gravis. Ther Apher Dial. 2010;14(2)153-160. 
Muppidi S, Wolfe GI, Conaway M,  Burns  TM; MG COMPOSITE  AND MG -QOL15 
STUDY GR OUP.  MG-ADL: st ill a re levant o utcome measure. Muscle Nerve. 20 11 
Nov;44(5):727-31 Nowak RJ.  Myasthenia Grav is: Challenges and Burdens  of Disease. Neu rology R eviews 
(suppl). 2018 Mar. 

 Immun ovant Sci ences GmbH  RVT-1401- 2002, Version 3 .0 
   
Conf idential 66 https://www.mdedge.com/neur ologyreviews/article/16 1081/myasthenia-gravis-
challenge s-and-burd ens-disease. Accessed 10 May 2018. 
Paul RH,  Nash JM, Cohen RA, Gilchrist JM , Goldstein J M. Quality of L ife and Wel l-
Being of Patie nts with  Myasthenia Gravis. Muscle Nerve.  2001;24:512-516. 
Pevzner A, Schoser B, Pet ers K, Cosma NC, Kara katsani A, Schalke B, Melms A, 
Kröger S. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody- negative myasthenia 
gravis. 2012 Mar;259(3) :427-35. 
Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of  age. Nat Rev 
Immunol. 2007 Sep;7(9):715-25. 
Sanders  DB, E voli A. Immunosuppres sive therapies in myasthenia gravis. 
Autoimmunity. 2010;45(5- 6):428-435. 
Sand ers DB, Wolfe G I, Benatar M, E voli A, Gilh us NE, I lla I, Kuntz N, Massey JM, 
Melms A, Murai H, Nicol le M,  Palace J, Richman DP , Verschuuren J, Naray anaswami P . 
International  consensus guidance for management of myasthenia gravis. Neurology. 2016 
Jul 26;87(4):419-25. Utsu gisawa K, S uzuki S, Nagane Y, Masud a M, Murai H, Imai T, Tsuda E, Konno S, 
Nakane S, Suzuki Y, Fujihara K, Suzuki N . Health -related quali ty of life and  treatment 
targets in myasthenia gravis. Muscle Nerve. 2014;50:493-500. 
Wolfe GI, Herbelin  L, Nations SP, Foster B, B ryan WW, Barohn R J. Mya sthenia gravis 
activities of daily living profile.  Neurology. 1999 Apr 22;52(7): 1487-9 
Zhang B, Tz artos JS, Belimezi  M, R agheb S, B ealmear B, Lewis RA, Xiong WC,  Lisak 
RP, Tzartos SJ, Mei L. Au toantibodies to lipoprotein- related pro tein 4 in patien ts with 
double-seronegative myasthenia gravis. Arch Neurol. 2012 Apr;69(4):445-51. Zisimopoulou P, Evangelakou P, Tz artos  J, Lazari dis K,  Zouvelou V, Mantegazza R, 
Antozzi C, Andreetta F, Evoli A, D eymeer F, Saruhan- Direskeneli G , Durmus H, 
Brenner T, Vaknin A, Be rrih-Aknin S, Frenkian Cuvelier M, Stojkovic T, De Baets  M, 
Losen M, Martinez- Martinez P, Kleopa KA , Zamba- Papanicolaou E, Kyriaki des T, 
Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Ba sta I, Peric S , Tallaksen C,  
Maniaol A,  Tzartos SJ. A com prehen sive analysis of  the epidemiology and clinical 
charac teristics of anti- LRP4 in m yasthenia gravis.  J Au toimmu n. 2014 Au g;52:139-45. 
 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 67 15. APPENDICES  
15.1.  Appendix 1: Abbreviations and Trademarks 
Abbrev iations 
AChR  Anti-acetylcholine  receptor  
ADA Anti-drug antibody  
AE Adverse event  
AESI  Adverse ev ent of special in terest 
ALT  Alanine aminot ransferase  
AST  Aspar tate aminot ransf erase 
AUC (0-t) Area under the concentration -time curve from time zero to 
time 
AUC ( 0-168) Area under the concentrati on-time curve fr om time zero to 
168 hour s 
AZA  Azathiopri ne  
BMI  Body mas s index 
BUN  Blood urea ni trogen 
CI Confidence  intervals  
Cmax  Maximum  concent ration 
CO 2 Carbon dioxide  
CPK  Serum creatine phosphokinase  
Cτ Concentratio n at end of dos ing interva l 
CV Cardiovasc ular 
ECG Electrocardiog ram 
eCRF  Electro nic case report f orm 
FcRn  fully human anti -neonatal FC receptor  
FDA  U.S. food and drug adminis tration  
FSH Follicle stimulatin g hormone  
GCP  Good Clinical Practice 
GGT  Gamma glutamyltra nsferase  
HBV Hepatitis B v irus 
HCV Hepatitis C vi rus 
HIV Human im munodeficiency vi rus 
IB Investigator’s bro chure 
ICF Informed c onsent form  
ICH International c onference on harmonisation  
IEC Independent ethics committee  
IgA Immunoglob ulin A 
IgG Imm unoglobulin  G 
IgM Immunogl obulin M  
IND Investigat ional new drug  
INR International normalized ratio 
IP Inves tigational product  
IRB Institut ional  review board 
 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 68 IS Immunosuppressive  
ITT Intent to treat  
IUD Intrauterine de vice 
IUS Intrau terine system  
IV Intraven ous 
IVIG  Intrav enous im munoglobulin  
IWRS Interactive We b Response System  
LDH Lactate dehydrogenas e 
MAD Multiple ascending dose 
MCH  Mean corpuscular hemoglobin  
MCHC  Mean corpuscula r hemoglobin concentration  
MCV Mean corpuscu lar volume  
MG Myasthenia Gravis 
MG-ADL  Myastheni a Gravis -Activit ies of Daily Living  
MGC  Myasthen ia Gravis Composite  
MGFA  Myas thenia Gravis Fou ndation of Ameri ca 
MG-QOL15r Myasthenia Gravis Quality of Life  
MedDRA  Medical dictionary f or regulatory ac tivities  
MSDS  Material sa fety data sheet  
MuSK Muscle-specific kinase receptor  
NAb Neutralizing A ntibody 
NSAID  Non-steroid al anti-inflammatory agents 
OLE  Open -label extens ion 
PD Pharm acodynamic  
PE Plasma exchange  
pIgG  Pathogenic IgG   
PIS Post-Intervention Stat us  
PK Pharm acokinetic  
QMG  Quantitati ve Myasthenia Gravis  
RBC Red blood cell  
SAD  Single ascending dose 
SAE  Serious adverse event  
SAP Statistical ana lysis plan 
SC Subcut aneous 
SD Standard de viation  
SRM  Study reference manual  
SUSAR  Suspected unexp ected serious  adverse reacti ons  
t1/2 Elimination ha lf-life 
TB Tuberculosis  
Tmax  Time t o maxi mum concentration  
ULN  Upper limit o f norma l 
WBC White blo od cell 
WHO-DDE  Worl d health o rganization drug dictionary enhanced  
 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 69  
 Trademark Information  
Tradema rks of Immunovant  Sciences 
GmbH   Tradem arks not owned by Immunovant  
Sciences GmbH  
  WinNo nlin 
  SAS 
  FlowJo  
  nSolver  
 
 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 70 15.2.  Appendix 2: Li ver Safety Required Actions and Follow up 
Assessments  
Liver  chemistry stopping criteria have been designed to assure pa rticipant safety and to 
evaluate live r event e tiology ( in alignment with  the FDA Drug -induced L iver Injury : 
Premarketing Clinical Ev aluat ion). 
http://www.fd a.gov/down loads/Dr ugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf. 
Liver Safe ty Proc ess 
The proc edures  listed be low are t o be foll owed if a participant  has ALT, bilirubin and/or 
INR elevatio ns that meet the defi nition of a SAE (as defined  in Sectio n 11):  
• Notify the medical monitor within 24 hours of lea rning of the abnorm ality to confirm 
follow-up. 
• Comple te the liver event case report forms .  
• Upon completion of the safety follow -up wi thdra w the participan t from the study 
unless further safety foll ow up is required. 
• Make every  reasonable attempt  to have particip ants return to the clinic within 24 
hours f or repeat liver chemistries, additional te sting, and close moni toring (with 
speciali st or hep atology  consultati on re comme nded). 
• Monitor participant s twice weekly  until liver chemistries (ALT, AST,  alkaline 
phospha tase, biliru bin) resolve, sta bilize o r return to within baseline values. 
• Obtain vir al hepatitis serology including: 
• Hepatitis A  IgM anti body. 
• Hepati tis B surfa ce antigen  and Hepat itis B Core Antibody (IgM).  
• Hepatitis C ribonucleic acid (R NA).   
• Cytomegalo virus IgM antibody. 
• Epstein -Barr vira l capsid anti gen IgM antibody (or if unavailable , obtain 
heterophile antibody or monospot testing).  
• Hepati tis E IgM antibody . 
• Serum creatine p hosphokinase (CPK) and lactate dehydrogenase (LDH).  
• Assess e osinophilia 
• Recor d the appearance o r worsening of clin ical symptoms  of hepatitis (fatigue, 
nausea, v omiting, right upper quadrant pain or tender ness,  fever, ras h or e osinophili a) 
on the AE e CRF.  
• Record use of concomitant medications, acetaminophen, herbal remedies, other over  
the counter me dications, or putative hepat otoxins on the Concomitant Medications 
eCRF.  
 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 71 • Record alcohol use on the Liver Even ts eCRF. 
• Anti-nuclear  antibody, anti-smoot h muscle antibody, Type 1 anti -liver kidney 
microso mal antibodies and quantitative tota l immunoglobulin G ( IgG or ga mma 
globulins). 
• Serum  acetaminophen adduct HPLC assay (quantifies potential a cetaminophen 
contribution to l iver in jury in par ticipants with definite o r likely acetamino phen use in 
the preceding week [ James , 2009]. NOT E: not r equired i n China  Liver ima ging 
(ultrasound, magnetic resonance, or computerized tomogr aphy) to evaluate liver 
disease.  
The Liver  Imaging an d/or Liver  Biopsy eC RFs are also  to be completed if these tests are 
performed.  
 
References  
James LP,  Letzig L, Simp son PM, Capparelli E, Robert s DW , Hinson JA, Davern TJ, Lee 
WM. Pha rmacokinetics of Acet aminophen-Adduct in Adults wit h Acetaminophen  
Overdos e and  Acute Liver Failure.  Drug Metab Dispos 2009; 37:1779-1784. 
 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 72  

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 73 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 74  

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 75 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 76 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 77 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 78 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 79 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 81 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 82 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 83 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 84 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 85  
 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 86 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 87 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 88 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 89 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 90 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
Confident ial 91 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 92 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 93 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 94 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 95 

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 96  

 Immunovant Sciences GmbH  RVT-1401- 2002, V ersion 3.0 
   
Confident ial 97 
